<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:40:55Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7932724" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7932724</identifier>
        <datestamp>2021-03-15</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7932724</article-id>
              <article-id pub-id-type="pmcid">PMC7932724</article-id>
              <article-id pub-id-type="pmc-uid">7932724</article-id>
              <article-id pub-id-type="pmid">33661917</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247257</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-20-35612</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Neurology</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Vascular Medicine</subject>
                    <subj-group>
                      <subject>Stroke</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Metabolism</subject>
                      <subj-group>
                        <subject>Metabolites</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                        <subj-group>
                          <subject>Ischemic Stroke</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Neurology</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                        <subj-group>
                          <subject>Ischemic Stroke</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Vascular Medicine</subject>
                    <subj-group>
                      <subject>Stroke</subject>
                      <subj-group>
                        <subject>Ischemic Stroke</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Behavior</subject>
                      <subj-group>
                        <subject>Habits</subject>
                        <subj-group>
                          <subject>Smoking Habits</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Social Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Behavior</subject>
                      <subj-group>
                        <subject>Habits</subject>
                        <subj-group>
                          <subject>Smoking Habits</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Cell biology</subject>
                    <subj-group>
                      <subject>Chromosome biology</subject>
                      <subj-group>
                        <subject>Chromatin</subject>
                        <subj-group>
                          <subject>Chromatin modification</subject>
                          <subj-group>
                            <subject>DNA methylation</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Genetics</subject>
                    <subj-group>
                      <subject>Epigenetics</subject>
                      <subj-group>
                        <subject>Chromatin</subject>
                        <subj-group>
                          <subject>Chromatin modification</subject>
                          <subj-group>
                            <subject>DNA methylation</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Genetics</subject>
                    <subj-group>
                      <subject>Gene expression</subject>
                      <subj-group>
                        <subject>Chromatin</subject>
                        <subj-group>
                          <subject>Chromatin modification</subject>
                          <subj-group>
                            <subject>DNA methylation</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Genetics</subject>
                    <subj-group>
                      <subject>DNA</subject>
                      <subj-group>
                        <subject>DNA modification</subject>
                        <subj-group>
                          <subject>DNA methylation</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Nucleic acids</subject>
                      <subj-group>
                        <subject>DNA</subject>
                        <subj-group>
                          <subject>DNA modification</subject>
                          <subj-group>
                            <subject>DNA methylation</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Genetics</subject>
                    <subj-group>
                      <subject>Epigenetics</subject>
                      <subj-group>
                        <subject>DNA modification</subject>
                        <subj-group>
                          <subject>DNA methylation</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Genetics</subject>
                    <subj-group>
                      <subject>Gene expression</subject>
                      <subj-group>
                        <subject>DNA modification</subject>
                        <subj-group>
                          <subject>DNA methylation</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Metabolism</subject>
                      <subj-group>
                        <subject>Metabolic Pathways</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Physical Sciences</subject>
                  <subj-group>
                    <subject>Chemistry</subject>
                    <subj-group>
                      <subject>Chemical Reactions</subject>
                      <subj-group>
                        <subject>Methylation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Lipids</subject>
                      <subj-group>
                        <subject>Sphingolipids</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Multi-omic analysis of stroke recurrence in African Americans from the Vitamin Intervention for Stroke Prevention (VISP) clinical trial</article-title>
                <alt-title alt-title-type="running-head">Multi-omic analysis of stroke recurrence in African Americans</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Davis Armstrong</surname>
                    <given-names>Nicole M.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Spragley</surname>
                    <given-names>Kelsey J.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Wei-Min</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hsu</surname>
                    <given-names>Fang-Chi</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brewer</surname>
                    <given-names>Michael S.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Horn</surname>
                    <given-names>Patrick J.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Williams</surname>
                    <given-names>Stephen R.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sale</surname>
                    <given-names>Michèle M.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Worrall</surname>
                    <given-names>Bradford B.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keene</surname>
                    <given-names>Keith L.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Department of Biology, East Carolina University, Greenville, North Carolina, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Department of Neurology, University of Virginia, Charlottesville, Virginia, United States of America</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Center for Health Disparities, Brody School of Medicine, East Carolina University, Greenville, North Carolina, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Zhan</surname>
                    <given-names>Frank Y.</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>German Centre for Neurodegenerative Diseases Site Munich: Deutsches Zentrum fur Neurodegenerative Erkrankungen Standort Munchen, GERMANY</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>keenek@ecu.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>4</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <volume>16</volume>
              <issue>3</issue>
              <elocation-id>e0247257</elocation-id>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>11</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>4</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 Davis Armstrong et al</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Davis Armstrong et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0247257.pdf"/>
              <abstract>
                <p>African Americans endure a nearly two-fold greater risk of suffering a stroke and are 2–3 times more likely to die from stroke compared to those of European ancestry. African Americans also have a greater risk of recurrent stroke and vascular events, which are deadlier and more disabling than incident stroke. Stroke is a multifactorial disease with both heritable and environmental risk factors. We conducted an integrative, multi-omic study on 922 plasma metabolites, 473,864 DNA methylation loci, and 556 variants from 50 African American participants of the Vitamin Intervention for Stroke Prevention clinical trial to help elucidate biomarkers contributing to recurrent stroke rates in this high risk population. Sixteen metabolites, including cotinine, N-delta-acetylornithine, and sphingomyelin (d17:1/24:1) were identified in t-tests of recurrent stroke outcome or baseline smoking status. Serum tricosanoyl sphingomyelin (d18:1/23:0) levels were significantly associated with recurrent stroke after adjusting for covariates in Cox Proportional Hazards models. Weighted Gene Co-expression Network Analysis identified moderate correlations between sphingolipid markers and clinical traits including days to recurrent stroke. Integrative analyses between genetic variants in sphingolipid pathway genes identified 29 nominal associations with metabolite levels in a one-way analysis of variance, while epigenomic analyses identified xenobiotics, predominately smoking-associated metabolites and pharmaceutical drugs, associated with methylation profiles. Taken together, our results suggest that metabolites, specifically those associated with sphingolipid metabolism, are potential plasma biomarkers for stroke recurrence in African Americans. Furthermore, genetic variation and DNA methylation may play a role in the regulation of these metabolites.</p>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000051</institution-id>
                      <institution>National Human Genome Research Institute</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U01HG005160</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Sale</surname>
                      <given-names>Michèle M.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution>National Human Genome Research Institute</institution>
                  </funding-source>
                  <award-id>U01HG005160</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Worrall</surname>
                      <given-names>Bradford B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution>National Human Genome Research Institute</institution>
                  </funding-source>
                  <award-id>U01HG005160-03S1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Sale</surname>
                      <given-names>Michèle M.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award004">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000051</institution-id>
                      <institution>National Human Genome Research Institute</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U01HG005160-03S1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Worrall</surname>
                      <given-names>Bradford B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award005">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000065</institution-id>
                      <institution>National Institute of Neurological Disorders and Stroke</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R15 NS095115-01A1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>Michael S.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award006">
                  <funding-source>
                    <institution>National Institute of Neurological Disorders and Stroke</institution>
                  </funding-source>
                  <award-id>R15 NS095115-01A1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Keene</surname>
                      <given-names>Keith L.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award007">
                  <funding-source>
                    <institution>National Institute of Neurological Disorders and Stroke</institution>
                  </funding-source>
                  <award-id>R15NS095115-01A1S1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>Michael S.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award008">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000065</institution-id>
                      <institution>National Institute of Neurological Disorders and Stroke</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R15NS095115-01A1S1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Keene</surname>
                      <given-names>Keith L.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award009">
                  <funding-source>
                    <institution>American Heart Association</institution>
                  </funding-source>
                  <award-id>Scientist Development Award 12SDG9180012</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Keene</surname>
                      <given-names>Keith L.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award010">
                  <funding-source>
                    <institution>Walking for My Life 5K Stroke Walk sponsored by Faith Christian Center International (Charlottesville, VA)</institution>
                  </funding-source>
                </award-group>
                <award-group id="award011">
                  <funding-source>
                    <institution>National Institute of Neurological Disorders and Stroke</institution>
                  </funding-source>
                  <award-id>R01NS34447</award-id>
                </award-group>
                <funding-statement>This work was supported by the National Institutes of Health, grant U01HG005160 and Supplement U01HG005160-03S1 (MMS/BBW) from the National Human Genome Research Institute, grant R15 NS095115-01A1 and Supplement R15NS095115-01A1S1 (KLK/MSB) from the National Institute of Neurological Disorders and Stroke, American Heart Association Scientist Development Award 12SDG9180012 (KLK), and funds from the Walking for My Life 5K Stroke Walk sponsored by Faith Christian Center International (Charlottesville, VA). The original study recruitment and datasets for the VISP clinical trial were supported by research grant R01 NS34447 (JT) from the National Institute of Neurological Disorders and Stroke.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="5"/>
                <page-count count="18"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>Individual level VISP genetic, metabolomics, and epigenetics data is considered sensitive controlled data and cannot be shared publicly, as specified by the IRBs of Wake Forest University School of Medicine, the University of North Carolina at Chapel Hill School of Medicine, and the University of Virginia School of Medicine, along with the NIH Data Access Committee. Controlled-access data can only be obtained if a user has been authorized by the appropriate Data Access Committee (DAC). The individual level Genomics and Randomized Trials Network (GARNET) VISP data are available in the database of Genotypes and Phenotypes (dbGaP) (Accession: phs000343.v3.p1) and can be requested through the dbGaP Authorized Access System (<ext-link ext-link-type="uri" xlink:href="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login">https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login</ext-link>), the Cerebrovascular Disease Knowledge Portal (<ext-link ext-link-type="uri" xlink:href="https://cd.hugeamp.org/">https://cd.hugeamp.org/</ext-link>), and the Coriell Institute for Medical Research (<ext-link ext-link-type="uri" xlink:href="https://catalog.coriell.org/">https://catalog.coriell.org/</ext-link>). The authors will also share the data on request.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>Individual level VISP genetic, metabolomics, and epigenetics data is considered sensitive controlled data and cannot be shared publicly, as specified by the IRBs of Wake Forest University School of Medicine, the University of North Carolina at Chapel Hill School of Medicine, and the University of Virginia School of Medicine, along with the NIH Data Access Committee. Controlled-access data can only be obtained if a user has been authorized by the appropriate Data Access Committee (DAC). The individual level Genomics and Randomized Trials Network (GARNET) VISP data are available in the database of Genotypes and Phenotypes (dbGaP) (Accession: phs000343.v3.p1) and can be requested through the dbGaP Authorized Access System (<ext-link ext-link-type="uri" xlink:href="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login">https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login</ext-link>), the Cerebrovascular Disease Knowledge Portal (<ext-link ext-link-type="uri" xlink:href="https://cd.hugeamp.org/">https://cd.hugeamp.org/</ext-link>), and the Coriell Institute for Medical Research (<ext-link ext-link-type="uri" xlink:href="https://catalog.coriell.org/">https://catalog.coriell.org/</ext-link>). The authors will also share the data on request.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>Stroke is a leading cause of death and disability globally, resulting in more than 6 million deaths per year [<xref rid="pone.0247257.ref001" ref-type="bibr">1</xref>]. For reasons yet to be elucidated, individuals of African descent are more likely to suffer a stroke, have an earlier age of occurrence, and experience poorer outcomes compared to individuals of other ancestry [<xref rid="pone.0247257.ref002" ref-type="bibr">2</xref>]. While overall stroke mortality rates have declined since 1990, the rates have remained higher among African Americans (AAs) than any other racial group in the United States. For example, stroke mortality rates are approximately 50% higher in AAs than their white counterparts with this mortality increasing with age (e.g. at age 55 the risk is up to three times greater) [<xref rid="pone.0247257.ref003" ref-type="bibr">3</xref>]. While racial disparities are prevalent in primary strokes, data on AAs and stroke recurrence are rare, even though recurrent strokes are more disabling and deadlier than initial strokes and account for 25% of annual cases [<xref rid="pone.0247257.ref001" ref-type="bibr">1</xref>]. The management of stroke risk factors, including hypertension and diabetes, remains an important strategy to decrease the stroke burden.</p>
              <p>The use of blood biomarkers that aid in stroke diagnosis and early identification of patients with high-risk of recurrence has been difficult to establish [<xref rid="pone.0247257.ref004" ref-type="bibr">4</xref>]. Part of this analytical complexity derives from the biologically complex set of associated effects, which can vary from person to person depending on the type of stroke, its severity, the location within the brain, number of strokes and recurrence, and other general health parameters. One of the most common approaches is to utilize a comparative analysis of core metabolites (e.g. amino acids, lipids, carbohydrates, coenzymes) quantified by mass spectrometric-based profiling of serum samples from stroke patients versus appropriate controls. Indeed, recent studies have identified several aberrant serum and urine metabolic biomarkers associated with stroke. For example, in a metabolomics analysis of 3,900 participants from the Atherosclerosis Risk in Communities Study (ARIC), two serum long-chain dicarboxylic acids, tetradecanedioate and hexadecanedioate (hazard ratio [95% confidence interval (CI)] 1.11 [1.06–1.16] and 1.12 [1.07–1.17], respectively), were associated with incident ischemic stroke [<xref rid="pone.0247257.ref005" ref-type="bibr">5</xref>]. In contrast, a smaller study of 40 patients with acute ischemic stroke more broadly identified potential metabolic biomarkers spanning amino acid, fatty acid, phospholipid, and choline metabolism pathways [<xref rid="pone.0247257.ref006" ref-type="bibr">6</xref>]. In a separate study of 67 cerebral infarction patients, metabolites that comprise the folate one-carbon cycle, including folic acid, cysteine, S-adenosyl homocysteine, and oxidized gluthaione, were determined as potential stroke biomarkers using an ultra-high-performance liquid chromatography in tandem with time of flight mass spectrometer (UPLC–TOF MS)-based metabolomic approach [<xref rid="pone.0247257.ref007" ref-type="bibr">7</xref>]. These few studies collectively demonstrate the complexity of analyzing metabolic events associated with stroke and identification of reliable biomarkers.</p>
              <p>In this current study, we conducted an integrative -omics analysis utilizing serum metabolites, DNA methylation, and genotype data from 50 African American participants from the Vitamin Intervention for Stroke Prevention (VISP) clinical trial. Like the aforementioned studies, metabolomics analyses of serum from stroke patients revealed additional metabolic biomarkers associated with recurrent stroke events. However, subsequent integration with genetics data has provided additional confidence in these event-metabolome associations and provides a foundation for future studies.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec002">
              <title>Methods</title>
              <sec id="sec003">
                <title>Ethics statement</title>
                <p>The VISP clinical trial study protocol was approved by the institutional review boards (IRBs) of Wake Forest University School of Medicine, the University of North Carolina at Chapel Hill School of Medicine, and individual recruitment sites. All VISP participants provided written, informed consent and a subset of 2,100 participants agreed to be included in subsequent genetic studies. IRB approval from the University of Virginia and East Carolina University was obtained for the genetic, epigenetic, and metabolomic components.</p>
              </sec>
              <sec id="sec004">
                <title>The Vitamin Intervention for Stroke Prevention (VISP) trial</title>
                <p>The Vitamin Intervention for Stroke Prevention (VISP) clinical trial was a multi-centered, double-blinded, randomized and controlled clinical trial designed to determine whether a combination pyridoxine (vitamin B6), cyanocobalamin (vitamin B12), and folic acid (vitamin B9) supplementation reduced recurrent cerebral infarction, myocardial infarction (MI), or fatal coronary heart disease [<xref rid="pone.0247257.ref008" ref-type="bibr">8</xref>]. Participants were enrolled within 120 days of suffering a non-disabling cerebral infarction, assigned a daily high-dose or low-dose B-vitamin formulation, and followed for two years. VISP inclusion/exclusion criteria are listed below.</p>
                <p>Inclusion criteria included:</p>
                <list list-type="order">
                  <list-item>
                    <p>Participants aged 35 years or older with elevated baseline homocysteine levels at or above the 25th percentile;</p>
                  </list-item>
                  <list-item>
                    <p>Participant enrollment within 120 days of suffering a non-disabling cerebral infarction characterized by the sudden onset of a neurological deficit persisting at least 24 hours and observed on CT or MRI;</p>
                  </list-item>
                  <list-item>
                    <p>Geographical accessibility for follow-up;</p>
                  </list-item>
                  <list-item>
                    <p>Adequate means of transportation;</p>
                  </list-item>
                  <list-item>
                    <p>Compliance of 75% or greater with vitamin regiment in the run-in period and</p>
                  </list-item>
                  <list-item>
                    <p>Patient agreement to take study medication and avoid other vitamin supplements containing folic acid and B6</p>
                  </list-item>
                </list>
                <p>VISP exclusion criteria included:</p>
                <list list-type="order">
                  <list-item>
                    <p>Stroke due to any form of intracranial hemorrhage, dissection of a cervico-cephalic artery, veno-occlusive disease, drug abuse, or vasculitis;</p>
                  </list-item>
                  <list-item>
                    <p>CT or MRI of brain showing lesion other than ischemic infarction as cause;</p>
                  </list-item>
                  <list-item>
                    <p>Modified Rankin Stroke Scale (RSS) score of 4–5 at time of eligibility determination;</p>
                  </list-item>
                  <list-item>
                    <p>Presence of specific potential sources of cardiogenic emboli, such as atrial fibrillation within 30 days of stroke or history of prosthetic cardiac valve, intracardiac thrombus or neoplasm, or valvular vegetation;</p>
                  </list-item>
                  <list-item>
                    <p>Presence of major neurologic illness apart from stroke that would prevent proper evaluation of recurrent stroke;</p>
                  </list-item>
                  <list-item>
                    <p>Presence of cancer, pulmonary disease, or other illness which, in the opinion of the study physician, would limit the life expectancy of the patient to less than two years;</p>
                  </list-item>
                  <list-item>
                    <p>Severe congestive heart failure;</p>
                  </list-item>
                  <list-item>
                    <p>Renal insufficiency requiring dialysis;</p>
                  </list-item>
                  <list-item>
                    <p>Untreated pernicious anemia or untreated B12 deficiency;</p>
                  </list-item>
                  <list-item>
                    <p>Uncontrolled hypertension defined as systolic blood pressure &gt;185 mm or diastolic &gt;105 mm on two readings separated by five minutes at time of eligibility determination;</p>
                  </list-item>
                  <list-item>
                    <p>Conditions that prevent reliable participation in the study, such as refractory depression, severe cognitive impairment, alcoholism, or other substance abuse;</p>
                  </list-item>
                  <list-item>
                    <p>Use of medications, within the last 30 days, that affect homocysteine, such as methotrexate, tamoxifen, L-dopa, or phenytoin or bile acid sequestrants that can decrease folate levels</p>
                  </list-item>
                  <list-item>
                    <p>Woman of childbearing potential, defined as not having reached natural or surgical menopause or having had tubal ligation;</p>
                  </list-item>
                  <list-item>
                    <p>Participation in another trial in which active intervention is being received;</p>
                  </list-item>
                  <list-item>
                    <p>Participants on multivitamin supplements or single vitamins of B6 or folic acid were excluded unless they were willing to take the study supplements in place of the one(s) they usually took and/or</p>
                  </list-item>
                  <list-item>
                    <p>Any surgical procedure requiring a general anesthesia or hospital stay of three days or more, any type of invasive cardiac instrumentation, or an endarterectomy, stent placement, thrombectomy, or any other endovascular treatment of an abnormal carotid artery performed within 30 days prior to randomization or scheduled to be performed within 30 days after randomization [<xref rid="pone.0247257.ref008" ref-type="bibr">8</xref>].</p>
                  </list-item>
                </list>
                <p>In this study, global metabolite data were generated from serum samples of 50 AAs, enriched for recurrent stroke cases (N = 28). When possible, nonrecurrent controls were matched with recurrent stroke cases for age (within eight years), sex, number of cigarettes smoked per day (within 5 cigarettes), and disability measured by the modified Rankin Stroke Scale (RSS; within two points) (<xref ref-type="supplementary-material" rid="pone.0247257.s002">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0247257.s003">S2</xref> Tables).</p>
              </sec>
              <sec id="sec005">
                <title>Stroke recurrence, vascular outcomes, and clinical trait definition</title>
                <p>In this study, recurrent stroke was defined as an acute neurological ischemic event of at least 24 hours duration with focal signs and symptoms and without evidence of primary intracranial hemorrhage or alternate explanation. Additionally, one of the following was present: 1) a one-point increase in the NIH stroke scale (NIHSS) in a previously normal section or 2) a new or 3) extended abnormality seen on CT or MRI. Diagnoses were reviewed by a local neurologist, two endpoint reviewers, and on a case-by-case basis, a Stroke Endpoint Review Committee. Underlying cause of death was decided by a Death Review Committee composed of physicians independent of VISP. Decisions were based on information available from hospital records, death certificates, coroners’ reports, or physicians’ questionnaires. Ischemic stroke subtype information is not available [<xref rid="pone.0247257.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0247257.ref009" ref-type="bibr">9</xref>]. Composite vascular event was defined as fatal coronary heart disease, a nonfatal hospitalized myocardial infarction (MI), and resuscitation for cardiac collapse, coronary bypass surgery, coronary angioplasty, or VISP recurrent stroke. Fatal/disabling stroke, MI, or death (FDMD) was defined as an outcome variable which identified individuals who suffered a disabling recurrent stroke or MI during the clinical trial or those who died from any cause. All of these outcomes were expressed as dichotomous variables and days from trial randomization to vascular event were recorded as time to event.</p>
                <p>The “recurrent stroke ever” variable indicated whether an individual had suffered a stroke in addition to the VISP enrollment stroke. The MI variable was indicative of an individual suffering a MI during the VISP clinical trial. Known stroke risk factors such as the number of cigarettes smoked per day, smoking status (at enrollment and ever), blood pressure (BP) measurements (systolic and diastolic), self-reported hypertension (HTN) status, diabetes status, the number of strokes prior to VISP, the treatment arm, age, sex, and body mass index (BMI) were included in analyses. Additionally, four stroke severity/functional scales were included: Mini-Mental State (MMS) status scale, NIHSS, RSS, and Barthel Stroke Questionnaire Form (BAR).</p>
              </sec>
              <sec id="sec006">
                <title>Metabolomics</title>
                <p>Global, untargeted metabolic profiling of 922 metabolites for the 50 AA VISP participants was performed by Metabolon, Inc (Durham, NC) using gas chromatography-mass spectrometry and liquid chromatographic-mass spectrometry protocols, as previously described [<xref rid="pone.0247257.ref010" ref-type="bibr">10</xref>]. Metabolite levels were measured using the fasting serum plasma samples from the baseline VISP visit.</p>
                <p>Supernatants from a methanol extraction were used for analyses by two reverse phase (RP) ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) methods with positive ion mode electrospray ionization (ESI); (RP) UPLC-MS/MS with negative ion mode ESI; and hydrophilic interaction liquid chromatography/UPLC-MS/MS with negative ion mode ESI. All methods utilized a Waters ACQUITY UPLC system (Waters Corporation, Milford, MA) and a Thermo Scientific Q-Exactive high resolution/accurate MS interfaced with a heated ESI source and Orbitrap mass analyzer (ThermoFisher Scientific, Waltham, MA). Raw data was extracted, peak-identified and processed using Metabolon’s proprietary hardware and software. Compounds were identified by comparison to library entries of purified standards or recurrent unknown entities that contain the retention time/index, mass to charge ratio, and chromatographic data, including tandem MS spectral data, on all molecules present in the library (<xref ref-type="supplementary-material" rid="pone.0247257.s001">S1 Appendix</xref>). Metabolite peaks were quantified using area-under-the-curve, and a data normalization step was performed to correct variation resulting from instrument inter-day tuning differences, setting the medians equal to one. A log transformation was performed on the normalized data for subsequent analysis.</p>
                <p>Instrument variability was determined by calculating the median relative standard deviation (RSD) for the internal standards that were added to each sample prior to injection into the mass spectrometers (median RSD = 3%). Overall process variability was determined by calculating the median RSD for all endogenous metabolites (median RSD = 9%). These values for instrument and process variability met Metabolon’s acceptance criteria.</p>
              </sec>
              <sec id="sec007">
                <title>DNA methylation</title>
                <p>As previously described, Illumina Infinium HumanMethylation450K BeadChip microarrays (Illumina, Inc., San Diego, CA, United States) were used per the manufacturer’s protocol to determine the degree of methylation (β values) for 485,512 methylation loci [<xref rid="pone.0247257.ref011" ref-type="bibr">11</xref>]. Quality control and quantile normalization was performed, resulting in 473,864 autosomal methylation CpG loci [<xref rid="pone.0247257.ref012" ref-type="bibr">12</xref>–<xref rid="pone.0247257.ref014" ref-type="bibr">14</xref>].</p>
              </sec>
              <sec id="sec008">
                <title>Genetic association of selected variants</title>
                <p>Previously, 2100 VISP participants were genotyped on the Illumina HumanOmni1-Quad_v1-0_B BeadChip (Illumina, Inc) [<xref rid="pone.0247257.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0247257.ref015" ref-type="bibr">15</xref>]. We selected 556 variants spanning ±10 kb of 24 genes associated with sphingolipid metabolism and the sphingomyelinase pathway (<xref ref-type="supplementary-material" rid="pone.0247257.s004">S3 Table</xref>). Individual level VISP genetic, metabolomics, and epigenetics data is considered sensitive controlled data and cannot be shared publicly, as specified by the IRBs of Wake Forest University School of Medicine, the University of North Carolina at Chapel Hill School of Medicine, and the University of Virginia School of Medicine, along with the NIH Data Access Committee. Controlled-access data can only be obtained if a user has been authorized by the appropriate Data Access Committee (DAC). The individual level Genomics and Randomized Trials Network (GARNET) VISP data are available in the database of Genotypes and Phenotypes (dbGaP) (Accession: phs000343.v3.p1) and can be requested through the dbGaP Authorized Access System (<ext-link ext-link-type="uri" xlink:href="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login">https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login</ext-link>), the Cerebrovascular Disease Knowledge Portal (<ext-link ext-link-type="uri" xlink:href="https://cd.hugeamp.org/">https://cd.hugeamp.org/</ext-link>), and the Coriell Institute for Medical Research (<ext-link ext-link-type="uri" xlink:href="https://catalog.coriell.org/">https://catalog.coriell.org/</ext-link>). The authors will also share the data on request.</p>
              </sec>
              <sec id="sec009">
                <title>Statistical analysis</title>
                <p>Baseline characteristics of the study participants with and without recurrent stroke were compared using t-tests and chi-squared (χ<sup>2</sup>) tests for continuous and categorical traits, respectively. Univariate Welch’s two sample t-tests were performed using all VISP participants (N = 50) and compared recurrent stroke, recurrent stroke ever, composite vascular event, and smoking statuses. VISP recurrent stroke analyses were stratified by sex, treatment arm, diabetes status (DM), and/or smoking status (<xref ref-type="supplementary-material" rid="pone.0247257.s005">S4 Table</xref>). A Bonferroni correction accounting for the number of metabolites tested was applied to determine the significance threshold of p≤ 5.42e-05 (error rate of 0.05 divided by the total number of metabolites, or = 0.05/922). A suggestive threshold of p≤4.42e-04 (= 0.05/113 total number of metabolite sub-pathways) was also implemented. Statistical power was calculated as 0.786, assuming a large effect size (Cohen’s d = 0.8) using the “pwr” package in R [<xref rid="pone.0247257.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0247257.ref017" ref-type="bibr">17</xref>].</p>
                <p>Matched pair analyses on a subset of 44 VISP participants (22 recurrent, 22 non-recurrent matched on age, sex, cigarettes smoked per day, and enrollment stroke severity) was conducted utilizing a matched-pair t-test. Statistical and suggestive significance was calculated as p≤5.42e-05 (Bonferroni adjustment described above) and p≤ 2.27e-03 (= 0.05/22 matched pairs), respectively. Statistical power of 0.8 was reached using a two-sided test, an effect size of 0.626, alpha = 0.05, and n = 22 matched pairs [<xref rid="pone.0247257.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0247257.ref017" ref-type="bibr">17</xref>].</p>
                <p>Cox proportional hazards (PHs) regression models were used to identify metabolites associated with time to event for VISP recurrent stroke or composite vascular event and adjusted for age, sex, and current smoking. Sensitivity models were formed adjusting for treatment and diabetes status. Conditional PH models adjusting for matched pairs was performed on the 22 pairs. Statistical and suggestive significance was determined as p≤5.42e-05 and p≤4.42e-04, respectively (see above for threshold determination) [<xref rid="pone.0247257.ref018" ref-type="bibr">18</xref>].</p>
                <p>A one-way analysis of variance (ANOVA) categorizing the genotypes (homozygous-dominant, heterozygous, homozygous-recessive) of 556 variants was implemented on all 305 sphingolipid and fatty acid metabolite levels. A Tukey’s HSD post-hoc test was performed to determine differences among genotypes. Statistical and suggestive significance was determined at p≤2.90e-09 (= 0.05/ (556 variants *305 sphingolipid and fatty acid metabolites)) and p≤8.99e-05 (= 0.05/556 variants), respectively.</p>
                <p>Weighted Gene Co-expression Network Analysis (WGCNA) [<xref rid="pone.0247257.ref019" ref-type="bibr">19</xref>] was calculated for: 1) clusters of metabolites and clinical traits; 2) clusters of metabolites and DNA methylation as traits; 3) clusters of DNA methylation and metabolite measures as traits; and 4) clusters of DNA methylation and clinical traits. Statistical and suggestive significance was calculated as 1) p≤2.26e-06 (= 0.05/(922 metabolites * 24 traits)) and p≤2.08e-03 (= 0.05/24 traits), respectively; 2) p≤1.14e-10 (= 0.05/(922 metabolites * 473864 loci)) and p ≤1.06e-07 (= 0.05/473864 loci), respectively; 3) p≤1.14e-10 (= 0.05/(922 metabolites * 473864 loci)) and p≤5.42e-05 (= 0.05/922 metabolites), respectively; and 4) p≤4.39e-09 (= 0.05/(473864 loci * 24 traits)) and p≤2.08e-03 (= 0.05/24 traits), respectively.</p>
                <p>In the metabolite cluster analyses, modules comprising the 922 metabolites were constructed using a soft-threshold power of 5. Pearson correlations between the first principal component (module eigenvalue) and trait (clinical or methylation beta values) were performed. WGCNA on the methylation profiles were performed and correlations between these modules and the metabolite profiles or clinical traits used the same quality control steps above. These modules were calculated using the blockwise module function, a soft-threshold power of 14, and a maximum block size of 10,000. Parameters for the module construction for all analyses consisted of the signed topographical overlap matrix type, a signed-hybrid network model, and the minimum number of loci set to 30.</p>
                <p>A multiple linear regression analysis adjusting for age, sex, batch effect, current smoking and estimated cellular proportions [<xref rid="pone.0247257.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0247257.ref021" ref-type="bibr">21</xref>] was performed to identify inferentially methylated CpG loci associated with metabolite measurements. Statistical and suggestive significance was determined at a threshold of p≤1.14e-10 (= 0.05/ (473864 loci*922 metabolites)) and p≤1.06e-07 (= 0.05/473856 CpG loci), respectively. Using the large effect size for regression (f2 = 0.35) with alpha of 0.05, degrees of freedom in the numerator and denominator of 13 and 35, respectively, resulted in a power of 0.6232 [<xref rid="pone.0247257.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0247257.ref017" ref-type="bibr">17</xref>]. All analyses were performed in R, version 3.5 [<xref rid="pone.0247257.ref022" ref-type="bibr">22</xref>].</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec010">
              <title>Results</title>
              <sec id="sec011">
                <title>Baseline demographics for VISP metabolomics subset</title>
                <p>Baseline characteristics of VISP study participants with and without recurrent stroke were compared using χ2 and t-tests for categorical and continuous variables, respectively, and are presented in <xref rid="pone.0247257.t001" ref-type="table">Table 1</xref>. Of the 50 participants, 56% (N = 28) suffered a recurrent stroke during the 2-year follow-up. The average baseline age of participants suffering a VISP recurrent stroke was approximately 1.5 years older than those who did not have stroke recurrence at ages 65.07 (standard deviation, SD 11.59) versus 63.68 (9.76), respectively. Those individuals who experienced a recurrent event had worse enrollment stroke severity based on the Modified Rankin Stroke Scale. Only one non-recurrent participant had moderate disability described as a Rankin score of 3, while 11 (39%) of the individuals who experienced stroke recurrence during the trial had moderate disability after the enrollment stroke (p&lt;0.001).</p>
                <table-wrap id="pone.0247257.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0247257.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Baseline demographics for VISP metabolomics subset.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0247257.t001g" xlink:href="pone.0247257.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="3" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1">VISP</th>
                          <th align="center" rowspan="1" colspan="1">VISP</th>
                          <th align="center" rowspan="3" colspan="1">P<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref></th>
                        </tr>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Nonrecurrent Stroke</th>
                          <th align="center" rowspan="1" colspan="1">Recurrent Stroke</th>
                        </tr>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">(N = 22)</th>
                          <th align="center" rowspan="1" colspan="1">(N = 28)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="1" colspan="1"><bold>Age,</bold> years<xref ref-type="table-fn" rid="t001fn002"><sup>b</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">63.68 (9.76)</td>
                          <td align="center" rowspan="1" colspan="1">65.07 (11.59)</td>
                          <td align="center" rowspan="1" colspan="1">0.654</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Sex</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.828</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Males</td>
                          <td align="center" rowspan="1" colspan="1">11 (50.0%)</td>
                          <td align="center" rowspan="1" colspan="1">16 (57.1%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Females</td>
                          <td align="center" rowspan="1" colspan="1">11 (50.0%)</td>
                          <td align="center" rowspan="1" colspan="1">12 (42.9%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Treatment Arm</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.973</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">High-dose</td>
                          <td align="center" rowspan="1" colspan="1">10 (45.5%)</td>
                          <td align="center" rowspan="1" colspan="1">14 (50.0%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Low-dose</td>
                          <td align="center" rowspan="1" colspan="1">12 (54.5%)</td>
                          <td align="center" rowspan="1" colspan="1">14 (50.0%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Current Smoker</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">4 (18.2%)</td>
                          <td align="center" rowspan="1" colspan="1">7 (25.0%)</td>
                          <td align="center" rowspan="1" colspan="1">0.815</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Smoker Ever</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">11 (50.0%)</td>
                          <td align="center" rowspan="1" colspan="1">18 (64.3%)</td>
                          <td align="center" rowspan="1" colspan="1">0.467</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Cigarettes per day</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">1.50 (3.67)</td>
                          <td align="center" rowspan="1" colspan="1">2.39 (5.55)</td>
                          <td align="center" rowspan="1" colspan="1">0.519</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Recurrent stroke ever</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">10 (45.5%)</td>
                          <td align="center" rowspan="1" colspan="1">28 (100%)</td>
                          <td align="center" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>HTN</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">20 (90.9%)</td>
                          <td align="center" rowspan="1" colspan="1">24 (85.7%)</td>
                          <td align="center" rowspan="1" colspan="1">0.902</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>DM</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">12 (54.5%)</td>
                          <td align="center" rowspan="1" colspan="1">8 (28.6%)</td>
                          <td align="center" rowspan="1" colspan="1">0.116</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>PNS</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.600</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="center" rowspan="1" colspan="1">12 (54.5%)</td>
                          <td align="center" rowspan="1" colspan="1">11 (40.7%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">8 (36.4%)</td>
                          <td align="center" rowspan="1" colspan="1">9 (33.3%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">2</td>
                          <td align="center" rowspan="1" colspan="1">1 (4.5%)</td>
                          <td align="center" rowspan="1" colspan="1">4 (14.8%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">1 (4.5%)</td>
                          <td align="center" rowspan="1" colspan="1">2 (7.4%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">4</td>
                          <td align="center" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="center" rowspan="1" colspan="1">1 (3.7%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Baseline BMI, kg/m</bold>
                            <sup>
                              <bold>2</bold>
                            </sup>
                          </td>
                          <td align="center" rowspan="1" colspan="1">29.70 (6.13)</td>
                          <td align="center" rowspan="1" colspan="1">28.92 (5.57)</td>
                          <td align="center" rowspan="1" colspan="1">0.639</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Baseline SBP, mmHg</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">146.41 (22.63)</td>
                          <td align="center" rowspan="1" colspan="1">143.82 (19.98)</td>
                          <td align="center" rowspan="1" colspan="1">0.670</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Baseline DBP, mmHg</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">81.64 (9.99)</td>
                          <td align="center" rowspan="1" colspan="1">79.57 (9.13)</td>
                          <td align="center" rowspan="1" colspan="1">0.450</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>RSS</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="center" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="center" rowspan="1" colspan="1">2 (7.1%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">13 (59.1%)</td>
                          <td align="center" rowspan="1" colspan="1">15 (53.6%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">2</td>
                          <td align="center" rowspan="1" colspan="1">8 (36.4%)</td>
                          <td align="center" rowspan="1" colspan="1">0 (0.00%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">1 (4.5%)</td>
                          <td align="center" rowspan="1" colspan="1">11 (39.3%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Days to VISP Stroke</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">NA</td>
                          <td align="center" rowspan="1" colspan="1">256.25 (212.85)</td>
                          <td align="center" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>Days to Composite Endpoint</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">552.23 (217.99)</td>
                          <td align="center" rowspan="1" colspan="1">262.57 (210.46)</td>
                          <td align="center" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p><sup>a</sup>p-value calculated using t-tests and χ<sup>2</sup> for continuous and categorical traits, respectively.</p>
                    </fn>
                    <fn id="t001fn002">
                      <p><sup>b</sup>Continuous traits described as mean (SD). Categorical traits described as N (%).</p>
                    </fn>
                    <fn id="t001fn003">
                      <p><bold>Abbreviations</bold>: HTN- hypertension; DM- baseline diabetes mellitus status; MI- myocardial infarction; PNS- previous number of strokes; SBP- systolic blood pressure; DBP- diastolic blood pressure; BMI- body mass index; RSS-modified Rankin Stroke Scale.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec012">
                <title>Identification of metabolites associated with VISP stroke recurrence</title>
                <p>Global, untargeted metabolic profiling of 922 metabolites was performed on each of the VISP participant serum samples. A series of statistical tests utilizing the metabolite profiles of VISP participants were performed, including a standard Welch’s <italic>t</italic>-test to account for unequal sample sizes and variances within the complete dataset, Cox proportional hazards regression analyses (Cox PH) to reveal associations between the survival time of VISP patients and metabolite detection, and one-sample <italic>t</italic>-tests for matched pair analyses. Collectively, these approaches identified seven significant and 25 suggestive metabolites associated with cardiovascular outcomes or associated clinical traits.</p>
                <p>Welch’s <italic>t</italic>-test identified 16 metabolites with significant (N = 6) or suggestive (N = 10) associations (<xref rid="pone.0247257.t002" ref-type="table">Table 2</xref>). Of these 16 metabolites, six were associated with recurrent stroke including N-delta-acetylornithine (male only VISP recurrence; p = 1.97e-05), 5α-androstane-3β,17β-diol monosulfate (recurrent stroke ever; p = 2.90e-04), sphingomyelin (d17:1/24:1) (high-dose VISP recurrence; p = 3.00e-04) and ceramide phosphoethanolamine (d18:1/16:0) (high-dose VISP recurrence; p = 3.10e-04). Five significant and five suggestive associations were identified in comparisons of smoking status at trial enrollment. The tobacco and cigarette smoking metabolites cotinine (p = 9.25e-13), 2-naphthol sulfate (p = 2.20e-09), and methylnapththyl sulfate (p = 7.35e-09), were the most significant associations observed.</p>
                <table-wrap id="pone.0247257.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0247257.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Significant associations from Welch’s <italic>t</italic>-test.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0247257.t002g" xlink:href="pone.0247257.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Phenotype</th>
                          <th align="center" rowspan="1" colspan="1">Metabolite</th>
                          <th align="center" rowspan="1" colspan="1">Pathway</th>
                          <th align="center" rowspan="1" colspan="1">Mean Difference (95% CI)</th>
                          <th align="center" rowspan="1" colspan="1"><italic>t</italic> stat (DF)</th>
                          <th align="center" rowspan="1" colspan="1">p value<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref></th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">cotinine</td>
                          <td align="center" rowspan="1" colspan="1">Tobacco Metabolite</td>
                          <td align="center" rowspan="1" colspan="1">-2.07 (-2.49, -1.65)</td>
                          <td align="center" rowspan="1" colspan="1">-10.01 (43)</td>
                          <td align="center" rowspan="1" colspan="1">9.25e-13</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">2-naphthol sulfate</td>
                          <td align="center" rowspan="1" colspan="1">Chemical</td>
                          <td align="center" rowspan="1" colspan="1">-0.77 (-0.97, -0.56)</td>
                          <td align="center" rowspan="1" colspan="1">-7.57 (43)</td>
                          <td align="center" rowspan="1" colspan="1">2.20e-09</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">methylnaphthyl sulfate</td>
                          <td align="center" rowspan="1" colspan="1">Fatty Acid Metabolism</td>
                          <td align="center" rowspan="1" colspan="1">-0.98 (-1.20, -0.76)</td>
                          <td align="center" rowspan="1" colspan="1">-9.40 (21)</td>
                          <td align="center" rowspan="1" colspan="1">7.35e-09</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">(2,4 or 2,5)-dimethylphenol sulfate</td>
                          <td align="center" rowspan="1" colspan="1">Food Component/Plant</td>
                          <td align="center" rowspan="1" colspan="1">-0.77 (-1.03, -0.51)</td>
                          <td align="center" rowspan="1" colspan="1">-6.16 (22)</td>
                          <td align="center" rowspan="1" colspan="1">3.81e-06</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Male VISP recurrent stroke: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">N-delta-acetylornithine</td>
                          <td align="center" rowspan="1" colspan="1">Urea cycle; Arginine and Proline Metabolism</td>
                          <td align="center" rowspan="1" colspan="1">0.39 (0.24, 0.54)</td>
                          <td align="center" rowspan="1" colspan="1">5.25 (25)</td>
                          <td align="center" rowspan="1" colspan="1">1.97e-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">o-cresol sulfate</td>
                          <td align="center" rowspan="1" colspan="1">Benzoate Metabolism</td>
                          <td align="center" rowspan="1" colspan="1">-0.81 (-1.13, -0.49)</td>
                          <td align="center" rowspan="1" colspan="1">-5.23 (22)</td>
                          <td align="center" rowspan="1" colspan="1">3.30e-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">2-ethylphenylsulfate</td>
                          <td align="center" rowspan="1" colspan="1">Benzoate Metabolism</td>
                          <td align="center" rowspan="1" colspan="1">-0.57 (-0.81, -0.34)</td>
                          <td align="center" rowspan="1" colspan="1">-5.28 (15)</td>
                          <td align="center" rowspan="1" colspan="1">1.10e-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Recurrent stroke ever: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">methyl-4-hydroxybenzoate sulfate</td>
                          <td align="center" rowspan="1" colspan="1">Benzoate Metabolism</td>
                          <td align="center" rowspan="1" colspan="1">-0.92 (-1.35, -0.49)</td>
                          <td align="center" rowspan="1" colspan="1">4.37 (34)</td>
                          <td align="center" rowspan="1" colspan="1">1.10e-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">indoleacetoylcarnitine</td>
                          <td align="center" rowspan="1" colspan="1">Tryptophan Metabolism</td>
                          <td align="center" rowspan="1" colspan="1">-0.54 (-0.78, -0.30</td>
                          <td align="center" rowspan="1" colspan="1">-4.66 (22)</td>
                          <td align="center" rowspan="1" colspan="1">1.20e-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">hydroxycotinine</td>
                          <td align="center" rowspan="1" colspan="1">Tobacco Metabolite</td>
                          <td align="center" rowspan="1" colspan="1">-1.19 (-1.69, -0.69)</td>
                          <td align="center" rowspan="1" colspan="1">-5.07 (16)</td>
                          <td align="center" rowspan="1" colspan="1">1.30e-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">No baseline DM VISP recurrence: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">quinate</td>
                          <td align="center" rowspan="1" colspan="1">Food Component/Plant</td>
                          <td align="center" rowspan="1" colspan="1">-0.97 (-1.45, 0.50)</td>
                          <td align="center" rowspan="1" colspan="1">4.19 (28)</td>
                          <td align="center" rowspan="1" colspan="1">2.60e-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Recurrent stroke ever: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">5α-androstan-3β,17β-diol monosulfate</td>
                          <td align="center" rowspan="1" colspan="1">Androgenic Steroids</td>
                          <td align="center" rowspan="1" colspan="1">0.27 (0.13, 0.41)</td>
                          <td align="center" rowspan="1" colspan="1">-3.93 (45)</td>
                          <td align="center" rowspan="1" colspan="1">2.90e-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">High-dose trial arm, VISP recurrence: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">sphingomyelin (d17:1/24:1)</td>
                          <td align="center" rowspan="1" colspan="1">Sphingomyelins</td>
                          <td align="center" rowspan="1" colspan="1">-0.21 (-0.30, -0.11)</td>
                          <td align="center" rowspan="1" colspan="1">4.45 (19)</td>
                          <td align="center" rowspan="1" colspan="1">3.00e-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">High-dose trial arm, VISP recurrence: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">ceramide phosphoethanolamine (d18:1/16:0)</td>
                          <td align="center" rowspan="1" colspan="1">Ceramide PEs</td>
                          <td align="center" rowspan="1" colspan="1">-0.16 (-0.24, -0.08)</td>
                          <td align="center" rowspan="1" colspan="1">4.44 (19)</td>
                          <td align="center" rowspan="1" colspan="1">3.10e-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">4-ethylphenylsulfate</td>
                          <td align="center" rowspan="1" colspan="1">Benzoate Metabolism</td>
                          <td align="center" rowspan="1" colspan="1">-0.44 (-0.66, -0.21)</td>
                          <td align="center" rowspan="1" colspan="1">-3.98 (31)</td>
                          <td align="center" rowspan="1" colspan="1">3.90e-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Baseline smoking: yes versus no</td>
                          <td align="center" rowspan="1" colspan="1">dimethyl sulfone</td>
                          <td align="center" rowspan="1" colspan="1">Chemical</td>
                          <td align="center" rowspan="1" colspan="1">0.30 (0.15, 0.45)</td>
                          <td align="center" rowspan="1" colspan="1">4.14 (23)</td>
                          <td align="center" rowspan="1" colspan="1">4.20e-04</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p><sup>a</sup> Statistical significance threshold: p≤5.42e-05 (<bold>bold</bold>); suggestive threshold: p≤4.42e-04.</p>
                    </fn>
                    <fn id="t002fn002">
                      <p><bold>Abbreviations:</bold> CI- confidence interval; DF- degrees of freedom; PE- phosphoethanolamine.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>In matched pair analyses, gamma-glutamylhistidine was identified as a metabolite with observed profile changes between recurrent stroke and non-recurrent participants (fold change, FC = 0.60, p = 3.10e-04) (<xref ref-type="supplementary-material" rid="pone.0247257.s006">S5 Table</xref>). While not reaching our <italic>a priori</italic> thresholds for significance, 18 sphingolipid metabolites had p-values less than 0.05, including sphingomyelin (d18:1/20:1) (FC = 0.77, p = 3.50e-03), sphingomyelin (d18:2/21:0) (FC = 0.66, p = 4.21e-03), and tricosanoyl sphingomyelin (d18:1/23:0) (FC = 0.72, p = 7.16e-03) (<xref ref-type="supplementary-material" rid="pone.0247257.s006">S5 Table</xref>).</p>
                <p>Cox PH survival analyses for the time to recurrent stroke identified tricosanoyl sphingomyelin (d18:1/23:0) (hazard ratio (HR): 0.002 [95% CI:0.000–0.036], p = 1.50e-05), as well as 11 suggestive associations; seven with time to recurrent stroke and four with composite vascular endpoint in the discovery model. Of the suggestively significant metabolites, 10 were associated with sphingomyelin metabolism. Threonate was independently associated with a composite vascular event (HR: 0.001 [0.001–0.135]; p = 4.00e-04) and not related to sphingolipid metabolism. Using global Schoenfeld residual tests, we did not observe any evidence of violation to the proportional hazards assumptions for any of the discovery models (p-values ranging from 0.26 to 0.537). Sensitivity models including the addition of treatment arm and diabetes status indicated consistent results for these 12 metabolites. A conditional Cox PH model adjusting for pair was performed and resulted in nominal significance for these metabolites (<xref rid="pone.0247257.t003" ref-type="table">Table 3</xref>).</p>
                <table-wrap id="pone.0247257.t003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0247257.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>Significant metabolite associations with time to event.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0247257.t003g" xlink:href="pone.0247257.t003"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="2" colspan="1">Phenotype</th>
                          <th align="center" rowspan="2" colspan="1">Metabolite</th>
                          <th align="center" colspan="5" rowspan="1">Discovery Model<xref ref-type="table-fn" rid="t003fn001"><sup>a</sup></xref></th>
                          <th align="center" colspan="3" rowspan="1">Sensitivity Analyses</th>
                        </tr>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">B</th>
                          <th align="center" rowspan="1" colspan="1">SE</th>
                          <th align="center" rowspan="1" colspan="1">HR (95% CI)</th>
                          <th align="center" rowspan="1" colspan="1">P<xref ref-type="table-fn" rid="t003fn005"><sup>e</sup></xref></th>
                          <th align="center" rowspan="1" colspan="1">Global Schoenfeld Residual P</th>
                          <th align="center" rowspan="1" colspan="1">Model 2<xref ref-type="table-fn" rid="t003fn002"><sup>b</sup></xref> P</th>
                          <th align="center" rowspan="1" colspan="1">Model 3<xref ref-type="table-fn" rid="t003fn003"><sup>c</sup></xref> P</th>
                          <th align="center" rowspan="1" colspan="1">Model 4<xref ref-type="table-fn" rid="t003fn004"><sup>d</sup></xref> P</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">VISP recurrent stroke</td>
                          <td align="center" rowspan="1" colspan="1">tricosanoyl sphingomyelin (d18:1/23:0)</td>
                          <td align="center" rowspan="1" colspan="1">-6.12</td>
                          <td align="center" rowspan="1" colspan="1">1.41</td>
                          <td align="center" rowspan="1" colspan="1">0.002 (0.000–0.035)</td>
                          <td align="center" rowspan="1" colspan="1">1.41E-05</td>
                          <td align="center" rowspan="1" colspan="1">0.537</td>
                          <td align="center" rowspan="1" colspan="1">1.55e-05</td>
                          <td align="center" rowspan="1" colspan="1">4.20E-05</td>
                          <td align="center" rowspan="1" colspan="1">5.97E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">VISP recurrent stroke</td>
                          <td align="center" rowspan="1" colspan="1">sphingomyelin (d18:1/21:0)</td>
                          <td align="center" rowspan="1" colspan="1">-5.17</td>
                          <td align="center" rowspan="1" colspan="1">1.29</td>
                          <td align="center" rowspan="1" colspan="1">0.005 (0.000–0.071)</td>
                          <td align="center" rowspan="1" colspan="1">6.21E-05</td>
                          <td align="center" rowspan="1" colspan="1">0.390</td>
                          <td align="center" rowspan="1" colspan="1">6.75e-05</td>
                          <td align="center" rowspan="1" colspan="1">1.06E-04</td>
                          <td align="center" rowspan="1" colspan="1">3.46E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">VISP recurrent stroke</td>
                          <td align="center" rowspan="1" colspan="1">behenoyl sphingomyelin (d18:1/22:0)</td>
                          <td align="center" rowspan="1" colspan="1">-5.40</td>
                          <td align="center" rowspan="1" colspan="1">1.36</td>
                          <td align="center" rowspan="1" colspan="1">0.005 (0.000–0.064)</td>
                          <td align="center" rowspan="1" colspan="1">6.92e-05</td>
                          <td align="center" rowspan="1" colspan="1">0.472</td>
                          <td align="center" rowspan="1" colspan="1">5.74e-05</td>
                          <td align="center" rowspan="1" colspan="1">1.70e-04</td>
                          <td align="center" rowspan="1" colspan="1">5.63E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Composite</td>
                          <td align="center" rowspan="1" colspan="1">tricosanoyl sphingomyelin (d18:1/23:0)</td>
                          <td align="center" rowspan="1" colspan="1">-5.32</td>
                          <td align="center" rowspan="1" colspan="1">1.35</td>
                          <td align="center" rowspan="1" colspan="1">0.005 (0.000–0.069)</td>
                          <td align="center" rowspan="1" colspan="1">8.15E-05</td>
                          <td align="center" rowspan="1" colspan="1">0.440</td>
                          <td align="center" rowspan="1" colspan="1">8.93E-05</td>
                          <td align="center" rowspan="1" colspan="1">1.37E-04</td>
                          <td align="center" rowspan="1" colspan="1">5.97E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Composite</td>
                          <td align="center" rowspan="1" colspan="1">sphingomyelin (d18:1/21:0)</td>
                          <td align="center" rowspan="1" colspan="1">-4.74</td>
                          <td align="center" rowspan="1" colspan="1">1.25</td>
                          <td align="center" rowspan="1" colspan="1">0.009 (0.001–0.099)</td>
                          <td align="center" rowspan="1" colspan="1">1.46E-04</td>
                          <td align="center" rowspan="1" colspan="1">0.260</td>
                          <td align="center" rowspan="1" colspan="1">1.52E-04</td>
                          <td align="center" rowspan="1" colspan="1">1.92E-04</td>
                          <td align="center" rowspan="1" colspan="1">3.46E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">VISP recurrent stroke</td>
                          <td align="center" rowspan="1" colspan="1">sphingomyelin (d18:2/23:0)</td>
                          <td align="center" rowspan="1" colspan="1">-5.97</td>
                          <td align="center" rowspan="1" colspan="1">1.58</td>
                          <td align="center" rowspan="1" colspan="1">0.003 (0.000–0.057)</td>
                          <td align="center" rowspan="1" colspan="1">1.59E-04</td>
                          <td align="center" rowspan="1" colspan="1">0.429</td>
                          <td align="center" rowspan="1" colspan="1">1.49E-04</td>
                          <td align="center" rowspan="1" colspan="1">3.04E-04</td>
                          <td align="center" rowspan="1" colspan="1">2.75E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">VISP recurrent stroke</td>
                          <td align="center" rowspan="1" colspan="1">sphingomyelin (d17:2/16:0)</td>
                          <td align="center" rowspan="1" colspan="1">-4.87</td>
                          <td align="center" rowspan="1" colspan="1">1.30</td>
                          <td align="center" rowspan="1" colspan="1">0.008 (0.001–0.098)</td>
                          <td align="center" rowspan="1" colspan="1">1.73E-04</td>
                          <td align="center" rowspan="1" colspan="1">0.350</td>
                          <td align="center" rowspan="1" colspan="1">1.73e-04</td>
                          <td align="center" rowspan="1" colspan="1">4.75E-04</td>
                          <td align="center" rowspan="1" colspan="1">2.24E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">VISP recurrent stroke</td>
                          <td align="center" rowspan="1" colspan="1">sphingomyelin (d18:2/21:0)</td>
                          <td align="center" rowspan="1" colspan="1">-4.72</td>
                          <td align="center" rowspan="1" colspan="1">1.26</td>
                          <td align="center" rowspan="1" colspan="1">0.009 (0.001–0.105)</td>
                          <td align="center" rowspan="1" colspan="1">1.79E-04</td>
                          <td align="center" rowspan="1" colspan="1">0.440</td>
                          <td align="center" rowspan="1" colspan="1">1.55E-04</td>
                          <td align="center" rowspan="1" colspan="1">2.37E-04</td>
                          <td align="center" rowspan="1" colspan="1">1.97E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">VISP recurrent stroke</td>
                          <td align="center" rowspan="1" colspan="1">lignoceroyl sphingomyelin (d18:1/24:0)</td>
                          <td align="center" rowspan="1" colspan="1">-4.51</td>
                          <td align="center" rowspan="1" colspan="1">1.22</td>
                          <td align="center" rowspan="1" colspan="1">0.011 (0.001–0.121)</td>
                          <td align="center" rowspan="1" colspan="1">2.25e-04</td>
                          <td align="center" rowspan="1" colspan="1">0.365</td>
                          <td align="center" rowspan="1" colspan="1">2.03E-04</td>
                          <td align="center" rowspan="1" colspan="1">5.72E-04</td>
                          <td align="center" rowspan="1" colspan="1">3.81E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">VISP recurrent stroke</td>
                          <td align="center" rowspan="1" colspan="1">sphingomyelin (d18:1/20:0)</td>
                          <td align="center" rowspan="1" colspan="1">-5.76</td>
                          <td align="center" rowspan="1" colspan="1">1.57</td>
                          <td align="center" rowspan="1" colspan="1">0.003 (0.000–0.068)</td>
                          <td align="center" rowspan="1" colspan="1">2.43E-04</td>
                          <td align="center" rowspan="1" colspan="1">0.310</td>
                          <td align="center" rowspan="1" colspan="1">2.32E-04</td>
                          <td align="center" rowspan="1" colspan="1">3.94E-04</td>
                          <td align="center" rowspan="1" colspan="1">3.23E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Composite</td>
                          <td align="center" rowspan="1" colspan="1">behenoyl sphingomyelin (d18:1/22:0)</td>
                          <td align="center" rowspan="1" colspan="1">-4.66</td>
                          <td align="center" rowspan="1" colspan="1">1.29</td>
                          <td align="center" rowspan="1" colspan="1">0.009 (0.001–0.122)</td>
                          <td align="center" rowspan="1" colspan="1">3.15E-04</td>
                          <td align="center" rowspan="1" colspan="1">0.383</td>
                          <td align="center" rowspan="1" colspan="1">3.13E-04</td>
                          <td align="center" rowspan="1" colspan="1">4.85E-04</td>
                          <td align="center" rowspan="1" colspan="1">5.63E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Composite</td>
                          <td align="center" rowspan="1" colspan="1">threonate</td>
                          <td align="center" rowspan="1" colspan="1">-4.49</td>
                          <td align="center" rowspan="1" colspan="1">1.26</td>
                          <td align="center" rowspan="1" colspan="1">0.011 (0.001–0.133)</td>
                          <td align="center" rowspan="1" colspan="1">3.70E-04</td>
                          <td align="center" rowspan="1" colspan="1">0.390</td>
                          <td align="center" rowspan="1" colspan="1">3.77E-04</td>
                          <td align="center" rowspan="1" colspan="1">5.84E-04</td>
                          <td align="center" rowspan="1" colspan="1">3.86E-02</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t003fn001">
                      <p><sup>a</sup> Discovery model adjusts for age, sex, current smoking.</p>
                    </fn>
                    <fn id="t003fn002">
                      <p><sup>b</sup> Model 2 adjusts for discovery model plus treatment arm.</p>
                    </fn>
                    <fn id="t003fn003">
                      <p><sup>c</sup> Model 3 adjusts for model 2 plus diabetes mellitus status.</p>
                    </fn>
                    <fn id="t003fn004">
                      <p><sup>d</sup> Model 4 is a conditional Cox proportional hazards model that adjusts for pair.</p>
                    </fn>
                    <fn id="t003fn005">
                      <p><sup>e</sup> Statistical significance threshold: p≤5.42e-05; suggestive threshold: p≤4.42e-04.</p>
                    </fn>
                    <fn id="t003fn006">
                      <p><bold>Abbreviations:</bold> B-beta coefficient; SE- standard error; HR- hazard ratio; CI- confidence interval; p- p-value.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>WGCNA analyses of metabolite clusters and clinical traits identified six minimal correlations for 45 VISP participants upon sample filtering (p≤0.01; <xref ref-type="fig" rid="pone.0247257.g001">Fig 1</xref>; <xref rid="pone.0247257.t004" ref-type="table">Table 4</xref>). The strongest correlation observed was between a module comprising 77 lipid metabolites (green module) and BMI (r = -0.44, p = 0.002). The yellow module incorporated 81 metabolites, mostly involved in sphingolipid metabolism, and was associated with three stroke outcomes including days to composite vascular endpoint (r = 0.40, p = 0.006), days to VISP recurrent stroke (r = 0.40, p = 0.007), and VISP recurrent stroke status (r = -0.36, p = 0.01).</p>
                <fig id="pone.0247257.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0247257.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>WGCNA for log transformed metabolite profiles of 45 AFR.</title>
                    <p>A.) Sample dendrogram and trait heatmap of metabolites and clinical traits/stroke outcomes B.) Module-trait heatmap of module eigenvalues and stroke outcomes.</p>
                  </caption>
                  <graphic xlink:href="pone.0247257.g001"/>
                </fig>
                <table-wrap id="pone.0247257.t004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0247257.t004</object-id>
                  <label>Table 4</label>
                  <caption>
                    <title>Top WGCNA module-trait associations for metabolite profiles and stroke traits/outcomes.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0247257.t004g" xlink:href="pone.0247257.t004"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Module</th>
                          <th align="center" rowspan="1" colspan="1"># of Metabolites/Module</th>
                          <th align="center" rowspan="1" colspan="1">Pathway<xref ref-type="table-fn" rid="t004fn001"><sup>a</sup></xref></th>
                          <th align="center" rowspan="1" colspan="1">Correlated Trait</th>
                          <th align="center" rowspan="1" colspan="1">r</th>
                          <th align="center" rowspan="1" colspan="1">P<xref ref-type="table-fn" rid="t004fn001"><sup>a</sup></xref></th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">green</td>
                          <td align="center" rowspan="1" colspan="1">77</td>
                          <td align="center" rowspan="1" colspan="1">Lipid metabolism (plasmalogen)</td>
                          <td align="center" rowspan="1" colspan="1">BMI</td>
                          <td align="center" rowspan="1" colspan="1">-0.44</td>
                          <td align="center" rowspan="1" colspan="1">0.002</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">brown</td>
                          <td align="center" rowspan="1" colspan="1">103</td>
                          <td align="center" rowspan="1" colspan="1">Amino acid metabolism (BCAA); Lipid metabolism (PC; PE)</td>
                          <td align="center" rowspan="1" colspan="1">DM</td>
                          <td align="center" rowspan="1" colspan="1">-0.43</td>
                          <td align="center" rowspan="1" colspan="1">0.003</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">yellow</td>
                          <td align="center" rowspan="1" colspan="1">81</td>
                          <td align="center" rowspan="1" colspan="1">Lipid metabolism (sphingomyelins)</td>
                          <td align="center" rowspan="1" colspan="1">Days to Composite Endpoint</td>
                          <td align="center" rowspan="1" colspan="1">0.40</td>
                          <td align="center" rowspan="1" colspan="1">0.006</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">yellow</td>
                          <td align="center" rowspan="1" colspan="1">81</td>
                          <td align="center" rowspan="1" colspan="1">Lipid metabolism (sphingomyelins)</td>
                          <td align="center" rowspan="1" colspan="1">Days to VISP Stroke</td>
                          <td align="center" rowspan="1" colspan="1">0.40</td>
                          <td align="center" rowspan="1" colspan="1">0.007</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">black</td>
                          <td align="center" rowspan="1" colspan="1">38</td>
                          <td align="center" rowspan="1" colspan="1">Lipid metabolism (androgenic, progestin steroids)</td>
                          <td align="center" rowspan="1" colspan="1">Sex</td>
                          <td align="center" rowspan="1" colspan="1">-0.36</td>
                          <td align="center" rowspan="1" colspan="1">0.01</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">yellow</td>
                          <td align="center" rowspan="1" colspan="1">81</td>
                          <td align="center" rowspan="1" colspan="1">Lipid metabolism (sphingomyelins)</td>
                          <td align="center" rowspan="1" colspan="1">VISP Stroke</td>
                          <td align="center" rowspan="1" colspan="1">-0.36</td>
                          <td align="center" rowspan="1" colspan="1">0.01</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t004fn001">
                      <p><sup><bold>a</bold></sup> Statistical significance threshold p≤2.26e-06; suggestive threshold: p≤2.08e-03.</p>
                    </fn>
                    <fn id="t004fn002">
                      <p><bold>Abbreviations:</bold> BCAA- branched chain amino acids; PC- phosphatidylcholine; PE- phosphatidylethanolamine; BMI- body mass index, kg/m<sup>2</sup>; DM-diabetes mellitus status</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec013">
                <title>Integrative metabolomics-genomics</title>
                <p>A one-way ANOVA was performed using the genotypes of 556 variants located within 10 kb upstream/downstream of 24 sphingolipid-metabolism-associated genes selected from the Harmonizome database [<xref rid="pone.0247257.ref023" ref-type="bibr">23</xref>] and the profiles of 305 sphingolipid/fatty acid metabolites (<xref ref-type="supplementary-material" rid="pone.0247257.s004">S3 Table</xref>). These analyses identified 29 variant-metabolite associations between 16 unique metabolites and 23 variants, that exceeded a suggestive threshold of p≤8.99e-05. Furthermore, Tukey’s post-hoc tests identified 54 differences among genotypes (<xref rid="pone.0247257.t005" ref-type="table">Table 5</xref>). The most significant association identified was between leukotriene B4 and rs7025659 (p = 6.12e-07; post-hoc comparison between TG-GG genotypes p = 3.00E-07), an upstream variant of <italic>SPTLC1</italic> (serine palmitoyltransferase long chain base subunit 1). Sphingosine and spinganine were nominally associated with five common variants and one distinct variant (rs10757056 (sphingosine only), rs10118089, rs7020745, rs10125228, rs10757058, rs10118371) in the region of <italic>ACER2</italic> encoding alkaline ceramidase 2 (<xref rid="pone.0247257.t005" ref-type="table">Table 5</xref>).</p>
                <table-wrap id="pone.0247257.t005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0247257.t005</object-id>
                  <label>Table 5</label>
                  <caption>
                    <title>Comparison between sphingolipid-associated variant genotype calls and mean metabolite level.</title>
                    <p>Sorted by ANOVA P value.</p>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0247257.t005g" xlink:href="pone.0247257.t005"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Metabolite</th>
                          <th align="center" rowspan="1" colspan="1">Variant</th>
                          <th align="center" rowspan="1" colspan="1">Closest Gene</th>
                          <th align="center" rowspan="1" colspan="1">ANOVA P<xref ref-type="table-fn" rid="t005fn001"><sup>a</sup></xref></th>
                          <th align="center" colspan="2" rowspan="1">Genotype Comparison</th>
                          <th align="center" rowspan="1" colspan="1">Tukey HSD P</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">leukotriene B4</td>
                          <td align="center" rowspan="2" colspan="1">rs7025659</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>SPTLC1</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">6.12E-07</td>
                          <td align="center" rowspan="1" colspan="1">TG</td>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">3.00E-07</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">TG</td>
                          <td align="center" rowspan="1" colspan="1">7.24E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">5-HETE</td>
                          <td align="center" rowspan="1" colspan="1">rs11601088</td>
                          <td align="center" rowspan="1" colspan="1">
                            <italic>SMPD1</italic>
                          </td>
                          <td align="center" rowspan="1" colspan="1">2.15E-05</td>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">AG</td>
                          <td align="center" rowspan="1" colspan="1">2.15E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">1-linoleoyl-GPE (18:2)</td>
                          <td align="center" rowspan="2" colspan="1">rs2898458</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ASAH1</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">2.24E-05</td>
                          <td align="center" rowspan="1" colspan="1">GA</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">1.69E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">GA</td>
                          <td align="center" rowspan="1" colspan="1">4.72E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">octadecadienedioate (C18:2-DC)</td>
                          <td align="center" rowspan="2" colspan="1">rs918957</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>CERS6-AS1</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">2.59E-05</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">CA</td>
                          <td align="center" rowspan="1" colspan="1">1.79E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">1.24E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">3-hydroxyoctanoate</td>
                          <td align="center" rowspan="2" colspan="1">rs7897345</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ASAH2B</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">2.80E-05</td>
                          <td align="center" rowspan="1" colspan="1">CT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">1.91E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">8.11E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">3-hydroxyoctanoate</td>
                          <td align="center" rowspan="2" colspan="1">rs13376734</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ASAH2B</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">2.80E-05</td>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">8.11E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">TC</td>
                          <td align="center" rowspan="1" colspan="1">1.91E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">2-hydroxyglutarate</td>
                          <td align="center" rowspan="2" colspan="1">rs1124626</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>CERS4</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">3.12E-05</td>
                          <td align="center" rowspan="1" colspan="1">AG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">5.13E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">1.75E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">2-hydroxyglutarate</td>
                          <td align="center" rowspan="2" colspan="1">rs11666971</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>CERS4</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">3.31E-05</td>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">1.87E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">GA</td>
                          <td align="center" rowspan="1" colspan="1">5.81E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphingosine</td>
                          <td align="center" rowspan="2" colspan="1">rs10757056</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">3.41E-05</td>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">4.14E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">TC</td>
                          <td align="center" rowspan="1" colspan="1">3.76E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphingosine</td>
                          <td align="center" rowspan="2" colspan="1">rs10118089</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">3.48E-05</td>
                          <td align="center" rowspan="1" colspan="1">AG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">3.04E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">3.67E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphingosine</td>
                          <td align="center" rowspan="2" colspan="1">rs7020745</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">3.48E-05</td>
                          <td align="center" rowspan="1" colspan="1">AC</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">3.04E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">3.67E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">1-palmitoyl-GPG (16:0)</td>
                          <td align="center" rowspan="2" colspan="1">rs135700</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>CERK</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">3.57E-05</td>
                          <td align="center" rowspan="1" colspan="1">TC</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">9.63E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">3.76E-02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">1-oleoyl-GPE (18:1)</td>
                          <td align="center" rowspan="2" colspan="1">rs2898458</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ASAH1</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">3.63E-05</td>
                          <td align="center" rowspan="1" colspan="1">GA</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">2.71E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">GA</td>
                          <td align="center" rowspan="1" colspan="1">6.25E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphinganine</td>
                          <td align="center" rowspan="2" colspan="1">rs10118089</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">5.07E-05</td>
                          <td align="center" rowspan="1" colspan="1">AG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">3.32E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">2.25E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphinganine</td>
                          <td align="center" rowspan="2" colspan="1">rs7020745</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">5.07E-05</td>
                          <td align="center" rowspan="1" colspan="1">AC</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">3.32E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">2.25E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">(S)-3-hydroxybutyrylcarnitine</td>
                          <td align="center" rowspan="2" colspan="1">rs12358176</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>SGMS1</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">5.11E-05</td>
                          <td align="center" rowspan="1" colspan="1">AG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">1.33E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">3.74E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">malonate</td>
                          <td align="center" rowspan="2" colspan="1">rs12355439</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>SGMS1</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">5.57E-05</td>
                          <td align="center" rowspan="1" colspan="1">CT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">5.47E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">3.27E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">malonate</td>
                          <td align="center" rowspan="2" colspan="1">rs11595661</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>SGMS1</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">5.57E-05</td>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">3.27E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">GA</td>
                          <td align="center" rowspan="1" colspan="1">5.47E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">palmitoyl-oleoyl-glycerol (16:0/18:1)</td>
                          <td align="center" rowspan="1" colspan="1">rs1466447</td>
                          <td align="center" rowspan="1" colspan="1">
                            <italic>CERS4</italic>
                          </td>
                          <td align="center" rowspan="1" colspan="1">5.72E-05</td>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CT</td>
                          <td align="center" rowspan="1" colspan="1">3.40E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphingosine</td>
                          <td align="center" rowspan="2" colspan="1">rs10125228</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">6.06E-05</td>
                          <td align="center" rowspan="1" colspan="1">AG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">5.04E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">4.46E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphinganine</td>
                          <td align="center" rowspan="2" colspan="1">rs10125228</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">6.41E-05</td>
                          <td align="center" rowspan="1" colspan="1">AG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">4.39E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">AA</td>
                          <td align="center" rowspan="1" colspan="1">2.78E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphingosine</td>
                          <td align="center" rowspan="2" colspan="1">rs10757058</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">6.96E-05</td>
                          <td align="center" rowspan="1" colspan="1">CT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">4.90E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">4.24E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphingosine</td>
                          <td align="center" rowspan="2" colspan="1">rs10118371</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">6.96E-05</td>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">4.24E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">TC</td>
                          <td align="center" rowspan="1" colspan="1">4.90E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphinganine</td>
                          <td align="center" rowspan="2" colspan="1">rs10757058</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">7.62E-05</td>
                          <td align="center" rowspan="1" colspan="1">CT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">4.66E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">2.68E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">sphinganine</td>
                          <td align="center" rowspan="2" colspan="1">rs10118371</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>ACER2</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">7.62E-05</td>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">2.68E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">TC</td>
                          <td align="center" rowspan="1" colspan="1">4.66E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">1-oleoyl-2-arachidonoyl-GP (18:1/20:4)</td>
                          <td align="center" rowspan="1" colspan="1">rs773280</td>
                          <td align="center" rowspan="1" colspan="1">
                            <italic>SPTLC1</italic>
                          </td>
                          <td align="center" rowspan="1" colspan="1">7.67E-05</td>
                          <td align="center" rowspan="1" colspan="1">TG</td>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">7.67E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">laurate (12:0)</td>
                          <td align="center" rowspan="2" colspan="1">rs10763500</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>SGMS1</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">7.68E-05</td>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">6.01E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">CT</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">2.39E-04</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">leukotriene B4</td>
                          <td align="center" rowspan="1" colspan="1">rs6721420</td>
                          <td align="center" rowspan="1" colspan="1">
                            <italic>CERS6</italic>
                          </td>
                          <td align="center" rowspan="1" colspan="1">7.81E-05</td>
                          <td align="center" rowspan="1" colspan="1">TT</td>
                          <td align="center" rowspan="1" colspan="1">CT</td>
                          <td align="center" rowspan="1" colspan="1">7.81E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">ceramide phosphoethanolamine (d18:1/16:0)</td>
                          <td align="center" rowspan="2" colspan="1">rs1047123</td>
                          <td align="center" rowspan="2" colspan="1">
                            <italic>CERK</italic>
                          </td>
                          <td align="center" rowspan="2" colspan="1">8.63E-05</td>
                          <td align="center" rowspan="1" colspan="1">GC</td>
                          <td align="center" rowspan="1" colspan="1">CC</td>
                          <td align="center" rowspan="1" colspan="1">8.09E-05</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">GG</td>
                          <td align="center" rowspan="1" colspan="1">GC</td>
                          <td align="center" rowspan="1" colspan="1">3.31E-02</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t005fn001">
                      <p><sup><bold>a</bold></sup> Statistical significance threshold: p≤2.90e-07; suggestive significance threshold: p≤8.99e-05.</p>
                    </fn>
                    <fn id="t005fn002">
                      <p><bold>Abbreviations</bold>: HSD- Honestly Significant Difference; <italic>ACER2-</italic> Alkaline Ceramidase 2; <italic>ASAH1-</italic> N-Acylsphingosine Amidohydrolase 1; <italic>ASAH2B-</italic> N-Acylsphingosine Amidohydrolase 2B; <italic>CERK-</italic> Ceramide Kinase; <italic>CERS4-</italic> Ceramide Synthase 4; <italic>CERS6-</italic> Ceramide Synthase 6; <italic>CERS6-AS1-</italic> CERS6 Antisense RNA 1; <italic>SGMS1-</italic> Sphingomyelin Synthase 1; <italic>SMPD1-</italic> Sphingomyelin Phosphodiesterase 1; <italic>SPTLC1-</italic> Serine Palmitoyltransferase Long Chain Base Subunit 1.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec014">
                <title>Integrative metabolomics-epigenomics</title>
                <p>WGCNA analyses of methylation modules and 39 clinical traits identified 14 associations that met or exceed p≤6.25e-06, of which nine were statistically significant (p≤2.71e-09). The two most significant associations were with number of strokes prior to enrollment and the thistle4 module (r = 0.91; p = 2.00e-18) and lightsteelblue1 module (r = -0.89; p = 6.00e-17). Other associations were detected with clinical biomarkers including baseline plasma folate, prothrombin fragments F1 + 2, thrombin-antithrombin complex, thrombomodulin, and triglycerides (<xref ref-type="supplementary-material" rid="pone.0247257.s007">S6 Table</xref>).</p>
                <p>WGCNA of methylation modules and metabolites identified 38 associations, of which 24 (22 significant and 2 suggestive) were between modules of methylation loci and pharmacological sub-pathways including analgesics/anesthetics (n = 7), cardiovascular (n = 6), gastrointestinal (n = 1), neurological (n = 2), psychoactive (n = 4), respiratory (n = 2), and topical agents (n = 2). Additional significant associations were found between the eicosanoid 5-hydroxyeicosatetraenoic acid and the brown4 (177 loci, r = -0.90, p = 2.00e-22) and lightpink3 modules (77 loci, r = 0.92, p = 3.00e-20), as well as threonylphenylalanine and the darkolivegreen (284 loci, r = -0.90, p = 5.00e-21) and the lightsteelblue1 (214 loci, r = 0.89, p = 8.00e-17) modules (<xref ref-type="supplementary-material" rid="pone.0247257.s008">S7 Table</xref>).</p>
                <p>Network associations between metabolite modules and methylation loci as traits detected 64 suggestive associations (p≤5.42e-05), with the strongest correlation observed between the green module (lysophospholipids and phosphatidylcholine synthesis) and cg18461635, a methylation locus in an intron of <italic>CCDC12</italic> (r = -0.65, p = 2.00e-06) (<xref ref-type="supplementary-material" rid="pone.0247257.s009">S8 Table</xref>).</p>
                <p>For tests of epigenetic-metabolite associations, linear regression analyses identified 2,622 methylation loci that met or exceeded p≤1.05e-07 (2-naphthol sulfate (n = 245), (2,4 or 2,5) dimethylphenol sulfate (n = 2,023), o-cresol-sulfate (n = 192), 2-ethylphenyl sulfate (n = 130), cotinine (n = 31), and hydroxycotinine (n = 1))(<xref ref-type="supplementary-material" rid="pone.0247257.s010">S9 Table</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec015">
              <title>Discussion</title>
              <p>This study integrated metabolomics, epigenomics, and genomics data in analyses of recurrent stroke in AAs. The metabolites identified in the baseline smoking <italic>t-</italic>test analysis included those present in tobacco or cigarette smoke. Cotinine, an alkaloid found in tobacco leaves and the main metabolite of nicotine, [<xref rid="pone.0247257.ref024" ref-type="bibr">24</xref>] was the most significant metabolite in a series of group-means comparisons. Serum cotinine levels have been used as an indicator of second-hand smoke exposure where high second-hand smoke levels (serum cotinine &gt;0.7 ng/mL) increased coronary heart disease risk up to 1.5-fold [<xref rid="pone.0247257.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0247257.ref026" ref-type="bibr">26</xref>]. In total, ten metabolites were detected in our smoking analyses. While these associations were significant, they were not surprising and serve as a proof-of-concept, validating the utility of metabolomics in the VISP study. Notable differences in the levels of N-delta-acetylornithine, sphingomyelin (d17:1/24:1), and ceramide phosphoethanolamine (d18:1/16:0) were observed in <italic>t-</italic>tests of stroke recurrence. N-delta-acetylornithine was previously associated with <italic>NAT8</italic>, a gene correlated with creatinine levels and chronic kidney disease in AA [<xref rid="pone.0247257.ref027" ref-type="bibr">27</xref>]. This is of interest since the risk of stroke is 5–30 times higher in patients with chronic kidney disease [<xref rid="pone.0247257.ref028" ref-type="bibr">28</xref>]. Identified in the matched pairs analysis, gamma-glutamylhistidine is a component of gamma-glutamyl amino acid metabolism. Previous studies suggested elevated gamma-glutamyl transferase is associated with increased risk of stroke, coronary heart disease, arterial HTN, and cardiovascular disease-related mortality [<xref rid="pone.0247257.ref029" ref-type="bibr">29</xref>].</p>
              <p>Sphingolipid-related metabolites were implicated in Welch’s <italic>t-</italic>tests, survival analyses, matched-pairs analysis, and WGCNA, where we observed an increase in sphingomyelin levels to confer a level of neuroprotection or delayed event recurrence. Sphingolipids play a vital role in intracellular signal transduction and regulation of cellular proliferation, maturation, apoptosis, and cellular stress response, as well as being components of the cardiomyocyte cell membrane [<xref rid="pone.0247257.ref030" ref-type="bibr">30</xref>]. Inflammatory cytokines, such as TNF-α, may induce the synthesis of ceramides from sphingomyelins via sphingomyelinase [<xref rid="pone.0247257.ref031" ref-type="bibr">31</xref>]. While numerous studies report detrimental effects associated with increased ceramide levels, sphingosine-1-phosphate (S1P), has a neuroprotective function during ischemia [<xref rid="pone.0247257.ref032" ref-type="bibr">32</xref>]. This is presumably due to S1P regulating pro-survival mechanisms through the suppression of pro-apoptotic factors including caspase 3 and the activation of protein kinase B or Akt [<xref rid="pone.0247257.ref032" ref-type="bibr">32</xref>]. Furthermore, increased ceramide levels have been reported in patients with HTN, with ceramide concentrations positively correlated with HTN severity [<xref rid="pone.0247257.ref033" ref-type="bibr">33</xref>]. Further investigation on the homeostatic balance between sphingomyelins and ceramides are needed to validate biological markers of stroke recurrence and stroke-related comorbidities such as HTN.</p>
              <p>Examining variants within sphingolipid metabolism enzymes identified 23 unique variants that were associated with metabolites within sphingolipid and fatty acid metabolism. In the present study, rs7025659 was associated with leukotriene B4, a pro-inflammatory lipid mediator derived from arachidonic acid [<xref rid="pone.0247257.ref034" ref-type="bibr">34</xref>]. Leukotriene B4 levels are associated with poorer functional recovery in ischemic stroke patients. A 2020 study reported that higher leukotriene B4 levels on days 0 and 7 post-ischemic stroke are associated with poorer functional recovery based on RSS [<xref rid="pone.0247257.ref034" ref-type="bibr">34</xref>]. Five genetic variants within <italic>ACER2</italic> were associated with plasma sphinganine and sphingosine levels, while an additional <italic>ACER2</italic> variant (rs10757056) was associated with sphingosine levels. <italic>ACER2</italic> encodes alkaline ceramidase 2, which hydrolyzes ceramides to generate sphingosine and sphingosine-1-phosphate [<xref rid="pone.0247257.ref035" ref-type="bibr">35</xref>]. <italic>ACER2</italic> expression is in-part regulated by the hypoxia-inducible factor 2α, an atherosclerosis suppressor and known ischemic stroke marker [<xref rid="pone.0247257.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0247257.ref037" ref-type="bibr">37</xref>]. Additionally, four variants within <italic>SGMS1</italic>, rs10763500, rs11595661, rs12355439, and rs12358176, were implicated in the ANOVA. <italic>SGMS1</italic> encodes the sphingomyelin synthase 1 protein, which is a transmembrane protein highly expressed in the brain [<xref rid="pone.0247257.ref038" ref-type="bibr">38</xref>] and functions by metabolizing ceramide into sphingomyelin [<xref rid="pone.0247257.ref039" ref-type="bibr">39</xref>]. While these results are promising, further studies with increased sample sizes are needed to determine the biological implications of these variants in regard to metabolism and stroke recurrence.</p>
              <p>Integrative analyses consisting of methylation, metabolite profiles, and covariates have reinforced our univariate results implicating tobacco and smoking related metabolites. This finding could strengthen the paradigm that secondhand smoke influences stroke and stroke recurrence [<xref rid="pone.0247257.ref040" ref-type="bibr">40</xref>]. Network analyses identified clusters of DNA methylation loci that were correlated with concentrations of prescribed analgesics, cardiovascular, neurological, and psychoactive drugs. These associations are to be expected in a population with individuals having suffered prior strokes and cardiovascular events, as these drugs are commonly prescribed to post-stroke patients. It is possible these drug associations could be useful for identifying individuals who are poor drug metabolizers or indicative of the efficacy and/or potency of particular therapeutics.</p>
              <p>This study was performed in a subset of AA VISP clinical trial participants, a population more likely to experience a recurrent stroke than their white counterparts. Furthermore, risk factors for stroke, specifically HTN, diabetes mellitus, and chronic kidney disease, are more prevalent in this population. The recurrent stroke phenotype overall is understudied and its etiology is not well understood; therefore, the multi-omic analyses on this complex disease is a strength of this study. DNA used in the methylation analyses was extracted from whole blood samples upon enrollment in the trial. Although not optimal due to cellular heterogeneity, whole blood provides a valuable resource that is available for replication studies. Adjusting for this limitation, cellular proportions were calculated <italic>in silico</italic>, and used as covariates in the association models.</p>
              <p>This study has a modest sample size of 50 individuals and thus our statistical power was limited and analyses could only confidently detect large effect associations. This was a primary drawback in addition to the lack of validation. Studies of AA with global metabolite, methylation, and genetic data, as well as adjudicated recurrent stroke outcomes are rare, further limiting our ability to include a replication cohort. Although stroke subtype is not adjudicated in VISP, these stroke cases most likely represent small vessel variety due to the inclusion/exclusion criteria and higher proportion of small vessel (lacunar) ischemic stroke typically overserved in AA [<xref rid="pone.0247257.ref041" ref-type="bibr">41</xref>].</p>
              <p>While the design of matched pairs is an optimal approach, in our analyses larger sample sizes could improve the detection of associations of small and/or medium effect size. Multiple blood samples per individual would allow for more comprehensive matched-pairs analyses, while matching based on similar pharmacological profiles and time of blood draw would be ideal as the consumption of pharmaceutical drugs, time of day, and time of year (i.e. season), all influence metabolite levels. We also cannot conclusively state that the metabolite levels were not altered by time post-stroke since the metabolites were collected within 120 days of stroke onset. Potentially acute metabolite profiles could differ from sub-acute or chronic stroke metabolite profiles. Additionally, samples should be matched closer to age, as our paired individuals were within eight years of age.</p>
              <p>In conclusion, even with a limited sample size, findings from this study provide insight into associations between metabolites, DNA methylation, genetic variants and recurrent stroke, thus identifying potential plasma biomarkers in AA. Further studies are needed to highlight the pathways underlying these associations in regard to their biological and clinical applications.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec016">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0247257.s001">
                <label>S1 Appendix</label>
                <caption>
                  <p>(XLSX)</p>
                </caption>
                <media xlink:href="pone.0247257.s001.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0247257.s002">
                <label>S1 Table</label>
                <caption>
                  <title>Baseline demographics of matched pairs.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247257.s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0247257.s003">
                <label>S2 Table</label>
                <caption>
                  <title>Demographics by pair.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247257.s003.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0247257.s004">
                <label>S3 Table</label>
                <caption>
                  <title>Sphingolipid related genes used in SNP-based tests.</title>
                  <p>Gene region based on hg19.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247257.s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0247257.s005">
                <label>S4 Table</label>
                <caption>
                  <title>Summary of Welch’s <italic>t-</italic>test comparisons.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247257.s005.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0247257.s006">
                <label>S5 Table</label>
                <caption>
                  <title>One-sample <italic>t</italic>-test of the fold change from 22 matched pairs.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247257.s006.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0247257.s007">
                <label>S6 Table</label>
                <caption>
                  <title>WGCNA module-trait associations for methylation profiles and stroke traits/outcomes.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247257.s007.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0247257.s008">
                <label>S7 Table</label>
                <caption>
                  <title>Significant WGCNA module (DNA methylation)-trait (metabolite) associations.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247257.s008.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0247257.s009">
                <label>S8 Table</label>
                <caption>
                  <title>WGCNA module (metabolite)-trait (DNA methylation loci) associations.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247257.s009.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0247257.s010">
                <label>S9 Table</label>
                <caption>
                  <title>Summary of significant metabolites-methylation associations using fully adjusted regression models.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247257.s010.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors would like to thank the individuals who participated in the VISP studies. We would additionally like to thank Gregory R. Wagner, PhD and Metabolon for generation of the metabolite data. Michele M. Sale passed away before the submission of the final version of this manuscript. The corresponding author (KLK) accepts responsibility for the integrity and validity of the data collected and analyzed.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0247257.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Virani</surname><given-names>SS</given-names></name>, <name><surname>Alonso</surname><given-names>A</given-names></name>, <name><surname>Benjamin</surname><given-names>EJ</given-names></name>, <name><surname>Bittencourt</surname><given-names>MS</given-names></name>, <name><surname>Callaway</surname><given-names>CW</given-names></name>, <name><surname>Carson</surname><given-names>AP</given-names></name>, <etal>et al</etal>. <article-title>Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association</article-title>. <source>Circulation</source>. <year>2020</year>;<volume>141</volume>(<issue>9</issue>):<fpage>e139</fpage>–<lpage>e596</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000757</pub-id>
<?supplied-pmid 31992061?><pub-id pub-id-type="pmid">31992061</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Owolabi</surname><given-names>M</given-names></name>, <name><surname>Sarfo</surname><given-names>F</given-names></name>, <name><surname>Howard</surname><given-names>VJ</given-names></name>, <name><surname>Irvin</surname><given-names>MR</given-names></name>, <name><surname>Gebregziabher</surname><given-names>M</given-names></name>, <name><surname>Akinyemi</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Stroke in Indigenous Africans, African Americans, and European Americans: Interplay of Racial and Geographic Factors</article-title>. <source>Stroke</source>. <year>2017</year>;<volume>48</volume>(<issue>5</issue>):<fpage>1169</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.116.015937</pub-id>
<?supplied-pmid 28389611?><pub-id pub-id-type="pmid">28389611</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Howard</surname><given-names>G</given-names></name>, <name><surname>Labarthe</surname><given-names>DR</given-names></name>, <name><surname>Hu</surname><given-names>J</given-names></name>, <name><surname>Yoon</surname><given-names>S</given-names></name>, <name><surname>Howard</surname><given-names>VJ</given-names></name>. <article-title>Regional differences in African Americans’ high risk for stroke: the remarkable burden of stroke for Southern African Americans</article-title>. <source>Ann Epidemiol</source>. <year>2007</year>;<volume>17</volume>(<issue>9</issue>):<fpage>689</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.annepidem.2007.03.019</pub-id>
<?supplied-pmid 17719482?><pub-id pub-id-type="pmid">17719482</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Sonderer</surname><given-names>J</given-names></name>, <name><surname>Katan Kahles</surname><given-names>M</given-names></name>. <article-title>Aetiological blood biomarkers of ischaemic stroke</article-title>. <source>Swiss Med Wkly</source>. <year>2015</year>;<volume>145</volume>:<fpage>w14138</fpage>. <pub-id pub-id-type="doi">10.4414/smw.2015.14138</pub-id><?supplied-pmid 26024210?><pub-id pub-id-type="pmid">26024210</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>D</given-names></name>, <name><surname>Tiedt</surname><given-names>S</given-names></name>, <name><surname>Yu</surname><given-names>B</given-names></name>, <name><surname>Jian</surname><given-names>X</given-names></name>, <name><surname>Gottesman</surname><given-names>RF</given-names></name>, <name><surname>Mosley</surname><given-names>TH</given-names></name>, <etal>et al</etal>. <article-title>A prospective study of serum metabolites and risk of ischemic stroke</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>92</volume>(<issue>16</issue>):<fpage>e1890</fpage>–<lpage>e8</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000007279</pub-id>
<?supplied-pmid 30867269?><pub-id pub-id-type="pmid">30867269</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>P</given-names></name>, <name><surname>Li</surname><given-names>R</given-names></name>, <name><surname>Antonov</surname><given-names>AA</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Hua</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Discovery of Metabolite Biomarkers for Acute Ischemic Stroke Progression</article-title>. <source>J Proteome Res</source>. <year>2017</year>;<volume>16</volume>(<issue>2</issue>):<fpage>773</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00779</pub-id>
<?supplied-pmid 28092160?><pub-id pub-id-type="pmid">28092160</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>Z</given-names></name>, <name><surname>Sun</surname><given-names>J</given-names></name>, <name><surname>Liang</surname><given-names>Q</given-names></name>, <name><surname>Cai</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>A metabonomic approach applied to predict patients with cerebral infarction</article-title>. <source>Talanta</source>. <year>2011</year>;<volume>84</volume>(<issue>2</issue>):<fpage>298</fpage>–<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/j.talanta.2011.01.015</pub-id>
<?supplied-pmid 21376948?><pub-id pub-id-type="pmid">21376948</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Toole</surname><given-names>JF</given-names></name>. <article-title>Vitamin intervention for stroke prevention</article-title>. <source>J Neurol Sci</source>. <year>2002</year>;<volume>203–204</volume>:<fpage>121</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/s0022-510x(02)00265-4</pub-id>
<?supplied-pmid 12417369?><pub-id pub-id-type="pmid">12417369</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>SR</given-names></name>, <name><surname>Yang</surname><given-names>Q</given-names></name>, <name><surname>Chen</surname><given-names>F</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Keene</surname><given-names>KL</given-names></name>, <name><surname>Jacques</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Genome-wide meta-analysis of homocysteine and methionine metabolism identifies five one carbon metabolism loci and a novel association of ALDH1L1 with ischemic stroke</article-title>. <source>PLoS Genet</source>. <year>2014</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e1004214</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1004214</pub-id><?supplied-pmid 24651765?><pub-id pub-id-type="pmid">24651765</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Evans</surname><given-names>AM</given-names></name>, <name><surname>DeHaven</surname><given-names>CD</given-names></name>, <name><surname>Barrett</surname><given-names>T</given-names></name>, <name><surname>Mitchell</surname><given-names>M</given-names></name>, <name><surname>Milgram</surname><given-names>E</given-names></name>. <article-title>Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems</article-title>. <source>Anal Chem</source>. <year>2009</year>;<volume>81</volume>(<issue>16</issue>):<fpage>6656</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1021/ac901536h</pub-id>
<?supplied-pmid 19624122?><pub-id pub-id-type="pmid">19624122</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Davis Armstrong</surname><given-names>NM</given-names></name>, <name><surname>Chen</surname><given-names>WM</given-names></name>, <name><surname>Brewer</surname><given-names>MS</given-names></name>, <name><surname>Williams</surname><given-names>SR</given-names></name>, <name><surname>Sale</surname><given-names>MM</given-names></name>, <name><surname>Worrall</surname><given-names>BB</given-names></name>, <etal>et al</etal>. <article-title>Epigenome-Wide Analyses Identify Two Novel Associations With Recurrent Stroke in the Vitamin Intervention for Stroke Prevention Clinical Trial</article-title>. <source>Front Genet</source>. <year>2018</year>;<volume>9</volume>:<fpage>358</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2018.00358</pub-id><?supplied-pmid 30237808?><pub-id pub-id-type="pmid">30237808</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Pidsley</surname><given-names>R</given-names></name>, <name><surname>CC</surname><given-names>YW</given-names></name>, <name><surname>Volta</surname><given-names>M</given-names></name>, <name><surname>Lunnon</surname><given-names>K</given-names></name>, <name><surname>Mill</surname><given-names>J</given-names></name>, <name><surname>Schalkwyk</surname><given-names>LC.</given-names></name><article-title>A data-driven approach to preprocessing Illumina 450K methylation array data</article-title>. <source>BMC Genomics</source>. <year>2013</year>;<volume>14</volume>:<fpage>293</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2164-14-293</pub-id><?supplied-pmid 23631413?><pub-id pub-id-type="pmid">23631413</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Aryee</surname><given-names>MJ</given-names></name>, <name><surname>Jaffe</surname><given-names>AE</given-names></name>, <name><surname>Corrada-Bravo</surname><given-names>H</given-names></name>, <name><surname>Ladd-Acosta</surname><given-names>C</given-names></name>, <name><surname>Feinberg</surname><given-names>AP</given-names></name>, <name><surname>Hansen</surname><given-names>KD</given-names></name>, <etal>et al</etal>. <article-title>Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1363</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btu049</pub-id>
<?supplied-pmid 24478339?><pub-id pub-id-type="pmid">24478339</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Touleimat</surname><given-names>N</given-names></name>, <name><surname>Tost</surname><given-names>J</given-names></name>. <article-title>Complete pipeline for Infinium((R)) Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation</article-title>. <source>Epigenomics</source>. <year>2012</year>;<volume>4</volume>(<issue>3</issue>):<fpage>325</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.2217/epi.12.21</pub-id>
<?supplied-pmid 22690668?><pub-id pub-id-type="pmid">22690668</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Keene</surname><given-names>KL</given-names></name>, <name><surname>Chen</surname><given-names>WM</given-names></name>, <name><surname>Chen</surname><given-names>F</given-names></name>, <name><surname>Williams</surname><given-names>SR</given-names></name>, <name><surname>Elkhatib</surname><given-names>SD</given-names></name>, <name><surname>Hsu</surname><given-names>FC</given-names></name>, <etal>et al</etal>. <article-title>Genetic Associations with Plasma B12, B6, and Folate Levels in an Ischemic Stroke Population from the Vitamin Intervention for Stroke Prevention (VISP) Trial</article-title>. <source>Front Public Health.</source><year>2014</year>;<volume>2</volume>:<fpage>112</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2014.00112</pub-id><?supplied-pmid 25147783?><pub-id pub-id-type="pmid">25147783</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Champley</surname><given-names>S</given-names></name>. <article-title>pwr: Basic Functions for Power Analysis</article-title>. <source>R package version 1.3–0</source>. <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="pone.0247257.ref017">
                <label>17</label>
                <mixed-citation publication-type="book"><name><surname>Cohen</surname><given-names>J</given-names></name>. <source>Statistical power analysis for the behavioral sciences</source>. <edition designator="2">2nd ed.</edition><publisher-loc>Hillsdale, N.J.</publisher-loc>: <publisher-name>L. Erlbaum Associates</publisher-name>; <year>1988</year>. <volume>xxi</volume>, 567 p. p.</mixed-citation>
              </ref>
              <ref id="pone.0247257.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Therneau</surname><given-names>T</given-names></name>. <article-title>A package for Survival Analysis in R</article-title>. <source>R packge version 3.2–3</source>. <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="pone.0247257.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Langfelder</surname><given-names>P</given-names></name>, <name><surname>Horvath</surname><given-names>S</given-names></name>. <article-title>WGCNA: an R package for weighted correlation network analysis</article-title>. <source>BMC Bioinformatics</source>. <year>2008</year>;<volume>9</volume>:<fpage>559</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id><?supplied-pmid 19114008?><pub-id pub-id-type="pmid">19114008</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Reinius</surname><given-names>LE</given-names></name>, <name><surname>Acevedo</surname><given-names>N</given-names></name>, <name><surname>Joerink</surname><given-names>M</given-names></name>, <name><surname>Pershagen</surname><given-names>G</given-names></name>, <name><surname>Dahlen</surname><given-names>SE</given-names></name>, <name><surname>Greco</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>7</issue>):<fpage>e41361</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0041361</pub-id><?supplied-pmid 22848472?><pub-id pub-id-type="pmid">22848472</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Houseman</surname><given-names>EA</given-names></name>, <name><surname>Accomando</surname><given-names>WP</given-names></name>, <name><surname>Koestler</surname><given-names>DC</given-names></name>, <name><surname>Christensen</surname><given-names>BC</given-names></name>, <name><surname>Marsit</surname><given-names>CJ</given-names></name>, <name><surname>Nelson</surname><given-names>HH</given-names></name>, <etal>et al</etal>. <article-title>DNA methylation arrays as surrogate measures of cell mixture distribution</article-title>. <source>BMC Bioinformatics</source>. <year>2012</year>;<volume>13</volume>:<fpage>86</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-13-86</pub-id><?supplied-pmid 22568884?><pub-id pub-id-type="pmid">22568884</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref022">
                <label>22</label>
                <mixed-citation publication-type="book"><name><surname>Team</surname><given-names>RDC</given-names></name>. <source>R: A Language and Environment for Statisitical Computing</source>. <publisher-loc>Vienna, Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>; <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="pone.0247257.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Rouillard</surname><given-names>AD</given-names></name>, <name><surname>Gundersen</surname><given-names>GW</given-names></name>, <name><surname>Fernandez</surname><given-names>NF</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Monteiro</surname><given-names>CD</given-names></name>, <name><surname>McDermott</surname><given-names>MG</given-names></name>, <etal>et al</etal>. <article-title>The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins</article-title>. <source>Database (Oxford)</source>. <year>2016</year>;<fpage>2016</fpage>. <pub-id pub-id-type="doi">10.1093/database/baw100</pub-id><?supplied-pmid 27374120?><pub-id pub-id-type="pmid">27374120</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Cheng</surname><given-names>T</given-names></name>, <name><surname>Gindulyte</surname><given-names>A</given-names></name>, <name><surname>He</surname><given-names>J</given-names></name>, <name><surname>He</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>PubChem 2019 update: improved access to chemical data</article-title>. <source>Nucleic Acids Res</source>. <year>2019</year>;<volume>47</volume>(<issue>D1</issue>):<fpage>D1102</fpage>–<lpage>D9</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1033</pub-id>
<?supplied-pmid 30371825?><pub-id pub-id-type="pmid">30371825</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Jefferis</surname><given-names>BJ</given-names></name>, <name><surname>Lawlor</surname><given-names>DA</given-names></name>, <name><surname>Ebrahim</surname><given-names>S</given-names></name>, <name><surname>Wannamethee</surname><given-names>SG</given-names></name>, <name><surname>Feyerabend</surname><given-names>C</given-names></name>, <name><surname>Doig</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Cotinine-assessed second-hand smoke exposure and risk of cardiovascular disease in older adults</article-title>. <source>Heart</source>. <year>2010</year>;<volume>96</volume>(<issue>11</issue>):<fpage>854</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/hrt.2009.191148</pub-id>
<?supplied-pmid 20478864?><pub-id pub-id-type="pmid">20478864</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Whincup</surname><given-names>PH</given-names></name>, <name><surname>Gilg</surname><given-names>JA</given-names></name>, <name><surname>Emberson</surname><given-names>JR</given-names></name>, <name><surname>Jarvis</surname><given-names>MJ</given-names></name>, <name><surname>Feyerabend</surname><given-names>C</given-names></name>, <name><surname>Bryant</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement</article-title>. <source>BMJ</source>. <year>2004</year>;<volume>329</volume>(<issue>7459</issue>):<fpage>200</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.38146.427188.55</pub-id>
<?supplied-pmid 15229131?><pub-id pub-id-type="pmid">15229131</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>B</given-names></name>, <name><surname>Zheng</surname><given-names>Y</given-names></name>, <name><surname>Alexander</surname><given-names>D</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Coresh</surname><given-names>J</given-names></name>, <name><surname>Boerwinkle</surname><given-names>E</given-names></name>. <article-title>Genetic determinants influencing human serum metabolome among African Americans</article-title>. <source>PLoS Genet</source>. <year>2014</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e1004212</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1004212</pub-id><?supplied-pmid 24625756?><pub-id pub-id-type="pmid">24625756</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Nayak-Rao</surname><given-names>S</given-names></name>, <name><surname>Shenoy</surname><given-names>MP</given-names></name>. <article-title>Stroke in Patients with Chronic Kidney Disease. . .: How do we Approach and Manage it?</article-title><source>Indian J Nephrol.</source><year>2017</year>;<volume>27</volume>(<issue>3</issue>):<fpage>167</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.4103/0971-4065.202405</pub-id>
<?supplied-pmid 28553032?><pub-id pub-id-type="pmid">28553032</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Ndrepepa</surname><given-names>G</given-names></name>, <name><surname>Kastrati</surname><given-names>A</given-names></name>. <article-title>Gamma-glutamyl transferase and cardiovascular disease</article-title>. <source>Ann Transl Med</source>. <year>2016</year>;<volume>4</volume>(<issue>24</issue>):<fpage>481</fpage>. <pub-id pub-id-type="doi">10.21037/atm.2016.12.27</pub-id><?supplied-pmid 28149843?><pub-id pub-id-type="pmid">28149843</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>N</given-names></name>, <name><surname>Keep</surname><given-names>RF</given-names></name>, <name><surname>Hua</surname><given-names>Y</given-names></name>, <name><surname>Xi</surname><given-names>G</given-names></name>. <article-title>Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets</article-title>. <source>Transl Stroke Res</source>. <year>2016</year>;<volume>7</volume>(<issue>5</issue>):<fpage>420</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1007/s12975-016-0477-3</pub-id>
<?supplied-pmid 27339463?><pub-id pub-id-type="pmid">27339463</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Borodzicz</surname><given-names>S</given-names></name>, <name><surname>Czarzasta</surname><given-names>K</given-names></name>, <name><surname>Kuch</surname><given-names>M</given-names></name>, <name><surname>Cudnoch-Jedrzejewska</surname><given-names>A</given-names></name>. <article-title>Sphingolipids in cardiovascular diseases and metabolic disorders</article-title>. <source>Lipids Health Dis</source>. <year>2015</year>;<volume>14</volume>:<fpage>55</fpage>. <pub-id pub-id-type="doi">10.1186/s12944-015-0053-y</pub-id><?supplied-pmid 26076974?><pub-id pub-id-type="pmid">26076974</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Hasegawa</surname><given-names>Y</given-names></name>, <name><surname>Suzuki</surname><given-names>H</given-names></name>, <name><surname>Sozen</surname><given-names>T</given-names></name>, <name><surname>Rolland</surname><given-names>W</given-names></name>, <name><surname>Zhang</surname><given-names>JH</given-names></name>. <article-title>Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats</article-title>. <source>Stroke</source>. <year>2010</year>;<volume>41</volume>(<issue>2</issue>):<fpage>368</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.109.568899</pub-id>
<?supplied-pmid 19940275?><pub-id pub-id-type="pmid">19940275</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Spijkers</surname><given-names>LJ</given-names></name>, <name><surname>van den Akker</surname><given-names>RF</given-names></name>, <name><surname>Janssen</surname><given-names>BJ</given-names></name>, <name><surname>Debets</surname><given-names>JJ</given-names></name>, <name><surname>De Mey</surname><given-names>JG</given-names></name>, <name><surname>Stroes</surname><given-names>ES</given-names></name>, <etal>et al</etal>. <article-title>Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>7</issue>):<fpage>e21817</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0021817</pub-id><?supplied-pmid 21818267?><pub-id pub-id-type="pmid">21818267</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>SJ</given-names></name>, <name><surname>Ng</surname><given-names>MPE</given-names></name>, <name><surname>Zhao</surname><given-names>H</given-names></name>, <name><surname>Ng</surname><given-names>GJL</given-names></name>, <name><surname>De Foo</surname><given-names>C</given-names></name>, <name><surname>Wong</surname><given-names>PT</given-names></name>, <etal>et al</etal>. <article-title>Early and Sustained Increases in Leukotriene B4 Levels Are Associated with Poor Clinical Outcome in Ischemic Stroke Patients</article-title>. <source>Neurotherapeutics</source>. <year>2020</year>;<volume>17</volume>(<issue>1</issue>):<fpage>282</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-019-00787-4</pub-id>
<?supplied-pmid 31520306?><pub-id pub-id-type="pmid">31520306</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>R</given-names></name>, <name><surname>Jin</surname><given-names>J</given-names></name>, <name><surname>Hu</surname><given-names>W</given-names></name>, <name><surname>Sun</surname><given-names>W</given-names></name>, <name><surname>Bielawski</surname><given-names>J</given-names></name>, <name><surname>Szulc</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P</article-title>. <source>FASEB J.</source><year>2006</year>;<volume>20</volume>(<issue>11</issue>):<fpage>1813</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1096/fj.05-5689com</pub-id>
<?supplied-pmid 16940153?><pub-id pub-id-type="pmid">16940153</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>, <name><surname>Zhang</surname><given-names>SY</given-names></name>, <name><surname>Dong</surname><given-names>Y</given-names></name>, <name><surname>Zeng</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Adipocyte Hypoxia-Inducible Factor 2alpha Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism</article-title>. <source>Cell Metab</source>. <year>2019</year>;<volume>30</volume>(<issue>5</issue>):<fpage>937</fpage>–<lpage>51 e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2019.09.016</pub-id>
<?supplied-pmid 31668872?><pub-id pub-id-type="pmid">31668872</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Du</surname><given-names>X</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>C</given-names></name>, <name><surname>Zhao</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Hypoxia-Inducible Factor 1alpha and 2alpha Have Beneficial Effects in Remote Ischemic Preconditioning Against Stroke by Modulating Inflammatory Responses in Aged Rats</article-title>. <source>Front Aging Neurosci</source>. <year>2020</year>;<volume>12</volume>:<fpage>54</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2020.00054</pub-id><?supplied-pmid 32210788?><pub-id pub-id-type="pmid">32210788</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref038">
                <label>38</label>
                <mixed-citation publication-type="other">Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple causes of death, 1999–2017. [Internet]. [cited April 1, 2019]. Available from: <ext-link ext-link-type="uri" xlink:href="https://wonder.cdc.gov/ucd-icd10.html">https://wonder.cdc.gov/ucd-icd10.html</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247257.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Yamaoka</surname><given-names>S</given-names></name>, <name><surname>Miyaji</surname><given-names>M</given-names></name>, <name><surname>Kitano</surname><given-names>T</given-names></name>, <name><surname>Umehara</surname><given-names>H</given-names></name>, <name><surname>Okazaki</surname><given-names>T</given-names></name>. <article-title>Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>(<issue>18</issue>):<fpage>18688</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M401205200</pub-id>
<?supplied-pmid 14976195?><pub-id pub-id-type="pmid">14976195</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>MP</given-names></name>, <name><surname>Ovbiagele</surname><given-names>B</given-names></name>, <name><surname>Markovic</surname><given-names>D</given-names></name>, <name><surname>Towfighi</surname><given-names>A</given-names></name>. <article-title>Association of Secondhand Smoke With Stroke Outcomes</article-title>. <source>Stroke</source>. <year>2016</year>;<volume>47</volume>(<issue>11</issue>):<fpage>2828</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.116.014099</pub-id>
<?supplied-pmid 27729574?><pub-id pub-id-type="pmid">27729574</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247257.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Gardener</surname><given-names>H</given-names></name>, <name><surname>Sacco</surname><given-names>RL</given-names></name>, <name><surname>Rundek</surname><given-names>T</given-names></name>, <name><surname>Battistella</surname><given-names>V</given-names></name>, <name><surname>Cheung</surname><given-names>YK</given-names></name>, <name><surname>Elkind</surname><given-names>MSV</given-names></name>. <article-title>Race and Ethnic Disparities in Stroke Incidence in the Northern Manhattan Study</article-title>. <source>Stroke</source>. <year>2020</year>;<volume>51</volume>(<issue>4</issue>):<fpage>1064</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.119.028806</pub-id>
<?supplied-pmid 32078475?><pub-id pub-id-type="pmid">32078475</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article id="pone.0247257.r001" article-type="aggregated-review-documents">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247257.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zhan</surname>
                    <given-names>Frank Y</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Frank Y Zhan</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Frank Y Zhan</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj001" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247257" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">24 Dec 2020</named-content>
              </p>
              <p>PONE-D-20-35612</p>
              <p>Multi-omic analysis of stroke recurrence in African Americans from the Vitamin Intervention for Stroke Prevention (VISP) clinical trial</p>
              <p>PLOS ONE</p>
              <p>Dear Dr. Keene,</p>
              <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
              <p>Please submit your revised manuscript by Feb 07 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
              <p>Please include the following items when submitting your revised manuscript:</p>
              <p>
                <list list-type="bullet">
                  <list-item>
                    <p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
                  </list-item>
                  <list-item>
                    <p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
                  </list-item>
                  <list-item>
                    <p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
                  </list-item>
                </list>
              </p>
              <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
              <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p>
              <p>We look forward to receiving your revised manuscript.</p>
              <p>Kind regards,</p>
              <p>Yiqiang Zhan</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Journal requirements:</p>
              <p>When submitting your revision, we need you to address these additional requirements.</p>
              <p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
              <p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p>
              <p>
                <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
              </p>
              <p>2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.</p>
              <p>[Note: HTML markup is below. Please do not edit.]</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>2. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>5. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: This study suggests results that are helpful in finding biomarkers related to stroke recurrence in high-risk groups.</p>
              <p>To further improve this research method, it would be better to describe the type of ischemic stroke or the lesion of the stroke in the subjects of this study. The relationship between these and biomarkers could lead to better research results.</p>
              <p>If this is not possible, it would be better to present it as a further study in the discussion.</p>
              <p>Reviewer #2: This manuscript is showing characteristic candidates of stroke based on metabolomics, genetic variations and epigenomics. statisitc analysis was carefully performed and the results showed interesting insights. Therefore, it is very excellent and acceptable for this journal.</p>
              <p>**********</p>
              <p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: <bold>Yes: </bold>Seung-Bo Yang</p>
              <p>Reviewer #2: <bold>Yes: </bold>Kazuo Ishii</p>
              <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
              <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
            </body>
          </sub-article>
          <sub-article id="pone.0247257.r002" article-type="author-comment">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247257.r002</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 0</article-title>
              </title-group>
              <related-article id="rel-obj002" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247257" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">2 Feb 2021</named-content>
              </p>
              <p>Reviewer #1: This study suggests results that are helpful in finding biomarkers related to stroke recurrence in high-risk groups.</p>
              <p>To further improve this research method, it would be better to describe the type of ischemic stroke or the lesion of the stroke in the subjects of this study. The relationship between these and biomarkers could lead to better research results.</p>
              <p>If this is not possible, it would be better to present it as a further study in the discussion.</p>
              <p>Reviewer #2: This manuscript is showing characteristic candidates of stroke based on metabolomics, genetic variations and epigenomics. statisitc analysis was carefully performed and the results showed interesting insights. Therefore, it is very excellent and acceptable for this journal.</p>
              <p>Response: Based on the inclusion and exclusion criteria for the VISP trial, the current study focuses on nondisabling ischemic stroke. The study specifically excluded those with stroke due to cardioembolic source including atrial fibrillation, arterial dissection, and moderate to severe carotid stenosis considered for surgical revascularization. Although ischemic stroke subtyping is not available for participants in VISP, the study population is comprised of patients with stroke primarily due to small vessel occlusion or intracranial large artery atherosclerosis with some individuals with non-surgical extracranial large artery atherosclerosis and cryptogenic/ undetermined stroke subtypes. We have modified the methods section by adding the inclusion/exclusion criteria and modified the discussion to reflect our statement above.</p>
              <supplementary-material content-type="local-data" id="pone.0247257.s011">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers .docx</named-content></p>
                </caption>
                <media xlink:href="pone.0247257.s011.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article id="pone.0247257.r003" article-type="editor-report">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247257.r003</article-id>
              <title-group>
                <article-title>Decision Letter 1</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zhan</surname>
                    <given-names>Frank Y</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Frank Y Zhan</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Frank Y Zhan</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj003" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247257" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">4 Feb 2021</named-content>
              </p>
              <p>Multi-omic analysis of stroke recurrence in African Americans from the Vitamin Intervention for Stroke Prevention (VISP) clinical trial</p>
              <p>PONE-D-20-35612R1</p>
              <p>Dear Dr. Keene,</p>
              <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
              <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
              <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="http://www.editorialmanager.com/pone/">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
              <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
              <p>Kind regards,</p>
              <p>Yiqiang Zhan</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Additional Editor Comments (optional):</p>
              <p>Reviewers' comments:</p>
            </body>
          </sub-article>
          <sub-article id="pone.0247257.r004" article-type="editor-report">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247257.r004</article-id>
              <title-group>
                <article-title>Acceptance letter</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zhan</surname>
                    <given-names>Frank Y</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Frank Y Zhan</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Frank Y Zhan</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj004" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247257" related-article-type="reviewed-article"/>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">22 Feb 2021</named-content>
              </p>
              <p>PONE-D-20-35612R1 </p>
              <p>Multi-omic analysis of stroke recurrence in African Americans from the Vitamin Intervention for Stroke Prevention (VISP) clinical trial </p>
              <p>Dear Dr. Keene:</p>
              <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
              <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
              <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
              <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
              <p>Kind regards, </p>
              <p>PLOS ONE Editorial Office Staff</p>
              <p>on behalf of</p>
              <p>Dr. Frank Y Zhan </p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
